Peptides, Vol. 5. Copyright © 1984 by ANKHO International Inc. Printed in the U.S.A.

PEPTIDES

Index to

VOLUME 5

1984

PEPTIDES

VOLUME 5 1984

SUBJECT INDEX

Acetylation, 1129
  α MSH
  neurointermediate lobe
  Xenopus laevis
Acid secretion, 277
  guinea pigs
  histamine H_2 receptor
  ultrastructure
  vasoactive intestinal peptide (VIP)
Acromegaly, 389
  cerebrospinal fluid
  growth hormone
  human studies
  prolactin
  vasoactive intestinal peptide (VIP)
ACTH
  corticosterone, 895
  β-endorphin, 713
  enkephalins, 895
  hyperthermia, 713
  naloxone, 895
  preoptic-anterior hypothalamus, 713
  tolerance, 713
ACTH 1–17, 507
  alimentary tract
  circadian rhythm
  DNA synthesis
$ACTH_{1-24}$, 659
  d-amphetamine self-administration
  brain dopamine
ACTH/MSH analog, 1061
  amygdala
  animal model
  infantile spasms
  kindling
Active site arginine, 769
  neuropeptide metabolism
  neurotensin
  neutral endopeptidase
  substance P
Active sleep, 25
  arginine vasotocin
  brain maturation
  kittens
Adenylate cyclase
  animal models, 341
  chronotyopic responses, 341
  cyclic AMP phosphodiesterase, 325
  dopamine, 1067
  Gila monster venom, 407
  heart membranes, 341
  heart membranes, human, 877
  hypertension, 355
  inotropic responses, 341
  mammotrophs, 1067
  peptide histidine isoleucine (PHI), 341
  platelet-activating factor, 325
  prolactinoma, 1067
  prostacyclin, 325
  rat pancreatic membranes, 407
  secretin, 341, 407
  strain differences, 355
  vasoactive intestinal peptide (VIP), 325, 341, 355, 407, 877, 1067
Adrenalectomy
  cardiovascular system, 801
  corticotropin releasing factor, 1077
  hypothalamus, 801
  localization, 1077
  preoptic area, 801
  stress, 1077
  thyrotropin-releasing hormone, 801
Adrenal medulla, 707
  corticotropin-releasing factor (CRF)
  immunoreactivity
  low molecular CRF
  tissue CRF
Adrenergic receptors, 499
  cholecystokinin
  hypothalamus
  in vivo studies
Age differences, s151
  noradrenaline
  supraoptic nucleus
  vasopressin-deficient neurons
Aged-rat brain, 53
  dihydroergotoxine
  enkephalin receptors
  thyrotropin releasing hormone receptors
Aggression
  arginine vasotocin, 1135
  isolation-induced fighting, 85
  opioids, 85
  pinealectomy, 1135
  substance P, 85
Aging
  Alzheimer's disease, s269
  brain, pig, 623
  cholecystokinin (CCK), 623, 889
  dopamine, s263
  fiber projection, 889
  immunoreactivity, 623
  mammillary body, 889
  neocortical transplants, 103
  neuropeptides, s269
  nigrostriatal system, s263
  nucleus anterior ventralis thalami, 889
  peptidergic neurons, 103
  vasoactive intestinal peptide (VIP), 623
Alimentary tract, 507
  ACTH 1–17
  circadian rhythm
  DNA synthesis
Allocortex-Brainstem-Core, s221
  endocrine-automatic regulation
  peptidergic-aminergic neuronal system
Alzheimer's disease, s269
  aging
  neuropeptides
Amastatin, 535
  aminopeptidase
  brain peptidases
  neuropeptide metabolism
  oxytocin
  vasopressin
Amino acid sequence, 959
  CCK biological activity
  cholecystokinin (CCK)
  human brain peptide
Aminopeptidase, 535
  amastatin
  brain peptidases
  neuropeptide metabolism
  oxytocin
  vasopressin
Aminopeptidase A, 789
  angiotensin I converting enzyme
  carboxypeptidase
  microvilli
  neutral endopeptidase
  placenta
d-Amphetamine self-administration, 659
  $ACTH_{1-24}$
  brain dopamine
Amphibians, 299
  calcium
  microfilaments
  prostaglandins
  vasoactive intestinal peptide (VIP)
Amygdala, 1129
  ACTH/MSH analog
  animal model
  infantile spasms
  kindling
Analgesia, 747
  pain
  tail-flick latencies
  vasopressin
Analgesic action, 463
  β-casomorphin
  isoreceptors
  μ-receptors
Angel dust, 967
  neuropeptides
  [^{3}H]-phencyclidine
  schizophrenia
Angiotensin I converting enzyme, 789
  aminopeptidase A
  carboxypeptidase
  microvilli

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

neutral endopeptidase
placenta
Angiotensin II
cell culture, 47
endorphin like immunoreactivity release, 47
intestinal fluid transport, 291
norepinephrine, 291
pituitary, rat, 47
vasoactive intestinal peptide (VIP), 291
Angiotensin II receptors, 1043
in vitro studies
kidney, dog
renal hypertension
Animal models
ACTH/MSH analog, 1061
adenylate cyclase, 341
amygdala, 1061
chronotropic responses, 341
heart membranes, 341
infantile spasms, 1061
inotropic responses, 341
kindling, 1061
peptide histidine isoleucine (PHI), 341
secretin, 341
vasoactive intestinal peptide (VIP), 341
Antagonist, 481
bovine parathyroid hormone
inhibition and stimulation
uterine contraction
Anterior pituitary corticotropes, 627
biotin-conjugated CRF analog
corticotropin (ACTH)
corticotropin releasing factor (CRF)
Anti-depressive effects, 743
behavioral despair rats
locomotor activity
thyrotropin releasing hormone (TRH)
TRH-analogues
Antipyresis, 57
antipyretic peptides
corticotropin releasing factor
fever
Antipyretic, 815
fever
alpha-melanocyte-stimulating hormone
rabbits
Antipyretic peptides, 57
antipyresis
corticotropin releasing factor
fever
Apparatus
intrathecal catheter, 477
multi-dimensional behavioral analyses, 1011
Sephadex G-50, 707
Arginine vasotocin
active sleep, 25
aggression, 1135
avoidance, 1221
brain maturation, 25
chickens, 1221
kittens, 25
memory, 1221
pinealectomy, 1135
Asthma, 439
bronchodilation
human studies
vasoactive intestinal peptide (VIP)
Atrial natriuretic factor
atrial natriuretic polypeptide, 1173
atriopeptins, 1173
autoradiography, 1167
brain peptides, 1167
cardiovascular system, 1167
receptor binding, 1167
Atrial natriuretic polypeptide, 1173
atrial natriuretic factor
atriopeptins
Atriopeptins, 1173
atrial natriuretic factor
atrial natriuretic polypeptide
Atropine treatment, 375
supersensitivity
vasoactive intestinal peptide (VIP)
VIP-levels
VIP-receptors
Autonomic nervous system
caudal neurosecretory system, s101
monkeys, s185
neuropeptides, s101
spinal cord, s185
thyrotropin-releasing hormone, s185
Autoradiography, 1167
atrial natriuretic factor
brain peptides
cardiovascular system
receptor binding
Autoregulation, 1225
hippocampal corticosterone
vasopressin
Aversion, s249
dementia
learning and memory
protein binding
Avoidance, 1221
arginine vasotocin
chickens
memory
Avoidance learning, 15
behavioral training
β-endorphin like immunoreactivity
protein malnutrition, postnatal
Axonal projections, s227
steroid hormone concentrating neurons

Bactericidal and phagocytic activity, 489
chemotaxis
polymorphonuclear leukocytes
tuftsin
Behavioral despair, rats, 743
anti-depressive effects
locomotor activity
thyrotropin releasing hormone (TRH)
TRH-analogues
Behavioral effects
cholecystokinin, 529
decortication of frontal neocortex, 899
dose-effect response curve, 899
open field, 529
proglumide, 529
thyrotropin releasing hormone, 899
Behavioral training, 15
avoidance learning
β-endorphin like immunoreactivity
protein malnutrition, postnatal
Binding assay, 917
neurotensin
purified plasma membranes
rat gastric fundus smooth muscle
Binding sites
human brain, 701
liver, pig, 367
neuropeptides, 367, 701
receptor-mediated degradation, 367
thyrotropin-releasing hormone, 701
vasoactive intestinal peptide (VIP), 367
Biological activities, 169
circular dichroism
peptide synthesis
vasoactive intestinal peptide (VIP)
Biosynthesis, 905
frogs
pituitary gland
pro-opiomelanocortin
Biotin-avidin technique, 931
enkephalin-like immunoreactivity
highly reactive neurons
rat hypothalamus
Biotin-conjugated CRF analog, 627
anterior pituitary corticotropes
corticotropin (ACTH)
corticotropin releasing factor (CRF)
Bladder motility, 645
central activity
endorphins
Blood-CSF barrier, 681
cerebrospinal fluid
inulin
α-MSH
Blood flow, 319
circulation
human studies
vasoactive intestinal peptide (VIP)
Blood mononuclear cells, 371
cyclic AMP-dependent protein kinase
vasoactive intestinal peptide (VIP)
Blood pressure
body temperature, 737
litorin, 765
D-Ala^2-Met-enkephalinamide, 737
monkeys, 737
opioid peptides, 737
phyllolitorins, 765
smooth muscle preparations, 765
Body temperature
blood pressure, 737
fever, 91
D-Ala^2-Met-enkephalinamide, 737
monkeys, 737
muramyl dipeptide, 91
opioid peptides, 737
sleep-induced peptides, 91
slow-wave sleep, 91
Body weight regulation, 547
bombesin
cholecystokinin
eating
lesions, dorsomedial hypothalamus
Bombesin
body weight regulation, 547
cholecystokinin, 547
dogs, 29
dopamine, 523
drinking, 607
eating, 547, 607
gastrin release, 29
lesions, dorsomedial hypothalamus, 547
litorin, 607
metabolites, 523
neuropeptides, 523
ranatensin, 607
somatostatin, 29

Bombesin-like immunoreactivity, 865
  human studies
  isolation
  sequencing
Bovine parathyroid hormone, 481
  antagonist
  inhibition and stimulation
  uterine contraction
Bovine PHI, 151
  brain-gut peptide
  human PHI
  peptide histidine isoleucine (PHI)
  VIP/PHI precursor
Brain
  adrenal medulla, s101, 707, 853
  allocortex, s221
  amygdala, s53, s91, s195, 339, 701, 953, 1129
  anterior hypothalamus, s157, s227, 801, 931
  anterior olfactory nucleus, s91
  anterior pituitary, 877, 937, 1017
  arcuate nucleus, s109, 1071
  area postrema, s221, 1167
  basal ganglia, 937
  bed nucleus, stria terminalis, s227, 1077
  blood-brain barrier, s249, 681, 1129
  brain stem, 209, 563, 721, 937
  caudate, 11, 659
  caudate-putamen, 669, 953
  cavernous plexus, 209
  central nervous system, 53, s53, s79, 81, s101, s249, 339, 523, 563, 585, 665, 681, 721, 833, 937, 1015, 1097
  cerebellar cortex, 1077
  cerebellum, 53, 209, 937
  cerebral cortex, 53, s53, 161, 209, 213, 375, 937, 1089
  cerebral ventricle, 125
  Circle of Willis, 209
  claustrum, 1077
  corpus luteum, 61
  cortex, 11, 73, s91, 623, 953, 967
  cuneiform nuclei, s53
  diencephalon, s91, 937
  dorsal caudal medulla, s227
  dorsal horn, 201, 569, 1179
  dorsal midbrain, s227
  dorsal root ganglia, 201
  dorsolateral funiculus, 201
  dorsomedial hypothalamus, 339, 547, 801
  dorsomedial nucleus, 1071
  dorsomedialis, 569
  external rete, 209
  fornix, 931
  frontal cortex, s269
  frontal neocortex, 899
  habenular complex, s195
  hindbrain, 11
  hippocampus, 11, 53, s53, 339, 563, 701, 967, 1077, 1089
  hypothalamus, 7, 11, s45, 53, 73, s91, s121, s169, s249, s269, 313, 499, 503, 523, 563, 569, 701, 801, 931, 953, 1017, 1071, 1213
  interpeduncular nucleus, 1077
  lateral hypothalamus, 41
  lateral retrochiasmatic area, s35
  lateral septum, 841, 1077
  lateral tegmental nucleus, s53
  locus ceruleus, s53, s221, 1077
  mammillary bodus, 1077
  medial basal hypothalamus, s195, s227
  medial perifornical region, 1071
  medial preoptic area, s53, 801
  median eminence, s35, s45, s109, s209, 841, 1071
  mediobasal hypothalamus, 669
  mesencephalon, s91
  midbrain, 11, 563, 937
  neocortex, 103, 1077
  nucleus accumbens, 1, s53, 659, 701, 953, 1077, 1207
  nucleus anterior ventralis thalami, 889
  nucleus arcuatus, 569
  nucleus caudatus putamen, 41
  nucleus centralis amygdalae, s221
  nucleus periventricularis, 1077
  nucleus tractus solitarii, s221, 1167
  olfactory bulb, 41, 53, s53, 1167
  olfactory tract, 1077
  olfactory tubercle, s53, 41, 523
  paleostriatum augmentatum, s91
  parabrachial nucleus, s53
  paraventricular nucleus, 569, 931
  periaqueductal gray, s53, 1077
  periventricular nucleus, s35, s45, s91, s109, s139, s227
  periventricular preoptic nuclei, s53
  piriform cortex, s91
  pituitary, s121, s221, s249
  posterior pituitary, s195
  preoptic-anterior hypothalamus, 713
  preoptic area, s227, 801, 931
  preoptic-septal nuclei, s221
  preoptic suprachiasmatic nucleus, 801
  raphe nuclei, s53
  rhinencephalon, 937
  rostral forebrain, s195
  septum, s53, 953
  spinal cord, 201, s227, 937
  stria terminalis, s53, s221
  striatum, 7, 53, 503, 523, 1207
  subfornical organ, 1167
  subiculum, 1077
  substantia gelatinosa, s221
  substantia nigra, s263, 953
  subthalamic nucleus, 1077
  superior colliculus, 1077
  suprachiasmatic nucleus, 313
  supraoptic nucleus, s35, s45, s53, s151
  sympathetic paravertebral ganglia, 195
  telencephalon, s91
  temporal cortex, 701
  thalamus, 11, s91, 339, 1077
  tractus solitarii, 569
  vagus nerve, 285
  ventral tegmental area of Tsai, s227
  ventral tegmentum, 953
  ventrobasal thalamic neuron, 1159
  ventrolateral ventromedial nucleus, s227
  ventromedial nucleus, 1071
  ventromedialis, 569
Brain dopamine, 659
  $ACTH_{1-24}$
  d-amphetamine self-administration
Brain-gut peptide, 151
  bovine PHI
  human PHI
  peptide histidine isoleucine (PHI)
  VIP/PHI precursor
Brain homogenates, 1191
  hormone stability
  melanocyte stimulating hormone
  melanotropins
Brain maturation, 25
  active sleep
  arginine vasotocin
  kittens
Brain opiocortins, 1089
  immunocytochemistry
  alpha MSH-specific neuronal system
Brain peptidases, 535
  amastatin
  aminopeptidase
  neuropeptide metabolism
  oxytocin
  vasopressin
Brain peptides
  atrial natriuretic factor, 1167
  autoradiography, 1167
  cardiovascular system, 1167
  GH release, s41
  growth hormone releasing factor, s41
  hormone action, s41
  pituitary hormones, s3
  receptor binding, 1167
  ultrashort loop feedback, s3
Brain, pig, 623
  aging
  cholecystokinin (CCK)
  immunoreactivity
  vasoactive intestinal peptide (VIP)
Bronchodilation, 439
  asthma
  human studies
  vasoactive intestinal peptide (VIP)

Calcitonin, 861
  calcitonin gene-related peptide
  eating
Calcitonin gene-related peptide
  calcitonin, 861
  central nervous system, 665
  eating, 861
  gastric acid secretion, 665
Calcium, 299
  amphibians
  microfilaments
  prostaglandins
  vasoactive intestinal peptide (VIP)
Caloric intake, 403
  gastric inhibitory polypeptide (GIP)
  human studies
  vasoactive intestinal peptide (VIP)
Cancer anorexia, 97
  cholecystokinin
  hypophagia
Carboxypeptidase, 789
  aminopeptidase A
  angiotensin I converting enzyme
  microvilli
  neutral endopeptidase
  placenta
Cardiovascular system
  adrenalectomy, 801
  atrial natriuretic factor, 1167
  autoradiography, 1167
  brain peptide, 1167
  hypothalamus, 801
  preoptic area, 801
  receptor binding, 1167
  thyrotropin-releasing hormone, 801

Casomorphins, 829
chicks
distress vocalizations
emotions
opioids
β-Casomorphin, 463
analgesic action
isoreceptors
μ-receptors
Castration, 1017
endo-oligopeptidase
gonadal steroids
Catalepsy, 883
haloperidol
Pro-Leu-Gly-NH_2
tolerance
Catecholamines
colon, human, 379
cyclic AMP, 379
hypothalamus, s109
neurotensin, s109
vasoactive intestinal peptide (VIP), 379
Catecholamine systems, 41
CCK-induced satiety
Cats
indirect immunofluorescence, 209
intrathecal injections, 477
shock titration, 477
substance P, 477
VIP-immunoreactive nerves, 209
Caudal neurosecretory system, s101
autonomic nervous system
neuropeptides
Caudate putamen, 669
DA uptake
medio basal hypothalamus
α-melanocyte-stimulating hormone
MSH-release inhibiting factor-1 (MIF-1)
C-blocked peptides, 653
N-formylation
CCK biological activity, 959
amino acid sequence
cholecystokinin (CCK)
human brain peptide
CCK-induced satiety, 41
catecholamine systems
Celiac disease, 1139
schizophrenia
wheat germ protein
Cell culture
angiotensin II, 47
endorphin like immunoreactivity release, 47
hypothalamo-neurohypophysinl system, s121
osmosensitivity, s121
pituitary, rat, 47
ultrastructure, s121
Central activity
bladder motility, 645
central nervous system, 1015
delta-opioid antagonism, 1015
endorphins, 645
ICI 174, 864, 1015
Central nervous system
calcitonin gene-related peptide, 665
central activity, 1015
corticotropin releasing factor, s53
delta-opioid antagonism, 1015
distribution, 721
FMRF amide immunoreactivity, 563, 585
gastric acid secretion, 665
gastrointestinal tract, 563
horseshoe crab, 585
ICI 174,864, 1015
immunocytochemistry, s53, 721
insulin, 937
insulin receptor subtype, 937
in vitro autoradiography, 339
lower brain stem, 721
α-melanocyte-stimulating hormone 721
nerve cell growth, 937
neuromodulators, 585
receptor binding kinetics, 937
substance P, 1097
substance P receptor, 1097
tachykinin, 1097
vasoactive intestinal peptide (VIP), 339
Cerebral cortex, 213
cortical organization
glycogenolysis
vasoactive intestinal peptide (VIP)
Cerebral cranial arteries, 385
dilator transmitter
extracerebral cranial arteries
vasoactive intestinal peptide (VIP)
Cerebrospinal fluid (CSF)
acromegaly, 389
blood-CSF barrier, 681
circadian variation, 429
epilepsy, 429
growth hormone, 389
human studies, 389, 435
inulin, 681
α-MSH, 681
multiple sclerosis, 435
neurological diseases, s255
neuropeptides, s255
prolactin, 389
vasoactive intestinal peptide (VIP), 389, 429, 435
Ceruletide
ceruletide analogues, 729
cholecystokinin, 1149
cholecystokinin octapeptide, 729
gallbladder, 729
guinea pigs, 729
lesions, ventromedial hypothalamus, 1149
route of administration, 1149
satiety, 1149
smooth muscle stimulation, 729
Ceruletide analogues, 729
ceruletide
cholecystokinin octapeptide
gallbladder
guinea pig
smooth muscle stimulation
Chemotaxis, 489
bactericidal and phagocytic activity
polymorphonuclear leukocytes
tuftsin
Chickens, 1221
arginine vasotocin
avoidance
memory
Chicks
casomorphins, 829
distress vocalizations, 823, 829
emotions, 823, 829
endorphins, 823
enkephalins, 823
opioids, 829
Chloramphenicol, 837
REM sleep
vasoactive intestinal peptide (VIP)
Chlordiazepoxide, 809
drug interaction
ethanol
pentobarbital
pigeons
thyrotropin releasing hormone
Cholecystokinin
adrenergic receptors, 499
aging, 623, 889
amino acid sequence, 959
behavioral effects, 529
body weight regulation, 547
bombesin, 547
brain, pig, 623
cancer anorexia, 97
CCK biological activity, 959
ceruletide, 1149
dopamine receptor, 1207
eating, 547
enkephalinase, 649
fiber projection, 889
gastric emptying, 481
genetic obesity, 11
guinea pigs, 285
human brain peptides, 959
hypophagia, 97
hypothalamus, 73, 499
immunoreactivity, 623
in vivo studies, 73, 499
lesions, dorsomedial hypothalamus, 547
lesions, ventromedial hypothalamus, 1149
mammillary body, 889
metalloendopeptidase, 649
methanol extraction, 1203
multiple neurotransmitter systems, 1
neuropeptide degradation, 649
nucleus accumbens, 1
nucleus anterior ventralis thalami, 889
obesity, 73
open field, 529
potentiation, 285
proglumide, 529
protein phosphorylation, 359
receptor binding, 11
route of administration, 1149
satiety, 481, 1149
secretin, 359
^{3}H-spiperone, 1207
C-terminal fragments, 1203
vagus nerve, 285
vasoactive intestinal peptide (VIP), 285, 359, 623
Cholecystokinin octapeptide, 729
ceruletide
ceruletide analogues
gallbladder
guinea pigs
smooth muscle stimulation
Chronotropic responses, 341
adenylate cyclase
animal models
heart membranes
inotropic responses
peptide histidine isoleucine (PHI)
secretin
vasoactive intestinal peptide (VIP)
Circadian rhythm
ACTH 1–17, 507
alimentary tract, 507
CRF, 1213

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V* . . . Suppl., Vol. 5, 1984.

delta sleep inducing peptide (DSIP), 495
DNA synthesis, 507
melatonin, 495
pituitary gland, 495
radioimmunoassay, 1213
Circadian variation, 429
cerebrospinal fluid
epilepsy
vasoactive intestinal peptide (VIP)
Circular dichroism, 169
biological activities
peptide synthesis
vasoactive intestinal peptide (VIP)
Circulation, 319
blood flow
human studies
vasoactive intestinal peptide (VIP)
Cloprostenol, 61
neurophysins
oxytocin
sheep
Coat color, mice, 1031
melanocyte sensitivity
α-MSH
Coeliac sprue, 411
duodenal ulcer
gastroduodenal mucosa
human studies
vasoactive intestinal peptide (VIP)
Colon, human, 379
catecholamines
cyclic AMP
vasoactive intestinal peptide (VIP)
Co-localisation, 255
peptide histidine isoleucine (PHI)
pigs
vasoactive intestinal peptide (VIP)
Competitive binding, 641
endogenous benzodiazepine ligands
GABA
human cerebrospinal fluid
Corneal epithelium, 945
epidermal growth factor
hypophysectomy
mitotic index
stomach weight
Cortical organization, 213
cerebral cortex
glycogenolysis
vasoactive intestinal peptide (VIP)
Corticosterone, 895
ACTH
enkephalins
naloxone
Corticotropin (ACTH)
anteriorpituitary corticotropes, 627
biotin-conjugated CRF analog, 627
corticotropin releasing factor (CRF), 627, 925
cortisol, 925
oxytocin, 519
pituitary ACTH release, 519
sauvagine, 925
urotensin I, 925
vasopressin-antagonists, 519
Corticotropin releasing factor (CRF)
adrenal medulla, 707
adrenalectomy, 1077
anterior pituitary corticotropes, 627
antipyresis, 57
antipyretic peptides, 57
biotin-conjugated CRF analog, 627
central nervous system, s53
circadian rhythms, 1213
corticotropin (ACTH), 627, 925
cortisol, 925
evolution, s71
fever, 57
hypothalamic hormones, s71
hypothalamus, s45
immunoenzyme techniques, s71
immunohistochemical localization of CRF, s45
immunoreactivity, 707
insulin secretion, 541
localization, 1077
low molecular CRF, 707
pancreas, 541
radioimmunoassay, 1213
sauvagine, 925
squirrel monkeys, s45
stress, 1077
surgical stress, 541
tissue CRF, 707
urotensin I, 925
Cortisol, 925
corticotropin (ACTH)
corticotropin releasing factor (CRF)
sauvagine
urotensin I
C-terminal fragments, 1203
cholecystokinin
methanol extraction
Cyclic AMP
catecholamines, 379
colon, human, 379
glycogenolysis, 295
neuropeptides, 295
retina, 295
vasoactive intestinal peptide (VIP), 295, 379
Cyclic AMP-dependent protein kinase, 371
blood mononuclear cells
vasoactive intestinal peptide (VIP)
Cyclic AMP phosphodiesterase, 325
adenylate cyclase
platelet-activating factor
prostacyclin
vasoactive intestinal peptide (VIP)
Cyclo (His-Pro), 133
frog skin
Cyclo (Leu-Gly), 7
D-2 dopamine receptors
hypothermia
stereotypy

DA uptake, 669
caudate putamen
mediobasal hypothalamus
α-melanocyte-stimulating hormone
MSH-release inhibiting factor-1 (MIF-1)
D cells, 615
immunocytochemistry
intestine
pancreas
radioimmunoassay
somatostatin 28
Decortication of frontal neocortex, 899
behavioral effects
dose-effect response curve
thyrotropin releasing hormone
Delta-opioid antagonism, 1015
central activity
central nervous system
ICI 174,864, 1015
Delta sleep inducing peptide (DSIP), 495
circadian rhythms
melatonin
pituitary gland
Dementia, s249
aversion
learning and memory
protein binding
Denervation, 219
urinary bladder
vasoactive intestinal peptide (VIP)
Dependence, 975
drinking
eating
endogenous opiates
stress
temperature
tolerance
Dermorphin, 687
guinea pig ileum
mouse vas deferens
structure-activity relationship
synthetic peptides
Desensitization, 797
dogs
down-regulation
methionine-enkephalin
opiate receptors
tolerance
Development, s157
in vitro studies
in vivo studies
regenerated cell cultures
transplantation
vasopressin
Diabetes insipidus, s169
neural transplantation
neuropeptides
neurosecretion
Diabetic pancreas, 451
immunocytochemistry
streptozotocin treatment
VIPergic innervation
Dihydroergotoxine, 53
aged-rat brain
enkephalin receptors
thyrotropin releasing hormone receptors
Dilatations, 329
human cerebral arteries
nerve fibers
vasoactive intestinal peptide (VIP)
Dilator transmitter, 385
cerebral cranial arteries
extracerebral cranial arteries
vasoactive intestinal peptide (VIP)
Distress vocalizations
casomorphins, 829
chicks, 823, 829
emotions, 823, 829
endorphins, 823
enkephalins, 823
opioids, 829
Distribution, 721
central nervous system
immunocytochemistry
lower brain stem
α-melanocyte-stimulating hormone

DNA synthesis, 507
ACTH 1–17
alimentary tract
circadian rhythm
Dogs
bombesin, 29
desensitization, 797
dopamine agonists, 399
down-regulation, 797
eating, 675
entero-insular axis, 445
food stimulation, 35
gastrin release, 29, 35
insulin hypoglycemia, 399
methionine-enkephalin, 797
opiate receptors, 797
pancreatic duct occlusion, 445
peptidergic regulation, 675
somatostatin, 29
tolerance, 797
vagotomy, 675
vasoactive intestinal peptide (VIP), 399, 445
Dopamine
adenylate cyclase, 1067
aging, s263
bombesin, 523
mammotrophs, 1067
metabolites, 523
neuropeptides, 523
nigrostriatal system, s263
prolactinoma, 1067
vasoactive intestinal peptide, 1067
Dopamine agonists, 399
dogs
insulin hypoglycemia
vasoactive intestinal peptide (VIP)
Dopamine receptor, 1207
cholecystokinin
^{3}H-spiperone
D-2 dopamine receptors, 7
cyclo (Leu-Gly)
hypothermia
stereotypy
Dorsal horn
neurotensin immunoreactivity
ultrastructure
Dose-effect response curve, 899
behavioral effects
decortication of frontal neocortex
thyrotropin releasing hormone
Down-regulation, 797
desensitization
dogs
methionine-enkephalin
opiate receptors
tolerance
Drinking
bombesin, 607
catecholamine systems, 41
CCK-induced satiety, 41
corticosterone, 47
dependence, 975
endogenous opiates, 975
β-endorphin, 691
litorin, 607
neuropeptide Y, 1025
opiates, 691
opioid peptides, 691
pigeons, 691
ranatensin, 607
stress, 975
temperature, 975
tolerance, 975
Drug
acetylcholine, 1
alcohol, 975
p-aminoclonidine, 499
amitriptyline, 743
d-amphetamine, 659
apomorphine, 7, 399, 659, 1031
atropine, 375, 385
bromocriptine, 399, 1031
capsaicin, 201
chloramphenicol, 837
chlordiazepoxide, 809
colchicine, 201
cycloheximide, 47
diazepam, 743
dihydroalprenolol, 499
dihydroergotoxine, 53
dithiothreitol, 407
DN-1417, 743
dopamine, 1, 7, 523, 1061, 1067
ES52, 1159
ethanol, s209, 809
glucagon, 341
halopemid, 399
haloperidol, 399, 659, 883, 1025
hexamethonium, 399
6-hydroxydopamine, 41
5-hydroxytryptamine, 313
histamine, 277, 439
insulin, 937
isoproterenol, 341, 499
methylatropine, 801
metyrapone, 913
MK-771, 743, 783
morphine, 1055
naloxone, 65, 85, 115, 129, 523, 645, 713, 737, 895, 1011, 1015, 1025, 1055
norepinephrine, 291
ORG-2766, 1129
pentobarbital, 809
[^{3}H]-phencyclidine, 967
phentolamine, 1025
proglumide, 481, 529
prostaglandin D_2, 395
saline, 291
serotonin, 523
streptozotocin, 451
tetrodoxin, 849
Drug interaction, 809
chlordiazepoxide
ethanol pentobarbital
pigeons
thyrotropin releasing hormone
Duodenal ulcer, 411
coeliac sprue
gastroduodenal mucosa
human studies
vasoactive intestinal peptide (VIP)

Eating
body weight regulation, 547
bombesin, 547, 607
calcitonin, 861
calcitonin gene-related peptide, 861
catecholamine systems, 41
CCK-induced satiety, 41
cholecystokinin, 547
dependence, 975
dogs, 675
endogenous opiates, 975
β-endorphin, 691
lesions, dorsomedial hypothalamus, 547
litorin, 607
neuropeptide Y, 1025
neuropeptides, 81
opiates, 691
opioid peptides, 691
peptidergic regulation, 675
pigeons, 691
ranatensin, 607
rumination, 81
sheep, 81
stress, 975
temperature, 975
tolerance, 975
vagotomy, 675
EEG voltage output, 115
hypophysectomy
postictal depression
Emotions
casomorphins, 829
chicks, 823, 829
distress vocalizations, 823, 829
endorphins, 823
enkephalins, 823
opioids, 829
Endocrine-automatic regulation, s221
Allocortex-Brainstem-Core
peptidergic-aminergic neuronal system
Endocrine-cell peptides, 21
isolated rat lungs
pulmonary vascular smooth muscle tone
Endogenous benzodiazepine ligands, 641
competitive binding
GABA
human cerebrospinal fluid
Endogenous opiates
dependence, 975
drinking, 975
eating, 975
glucose, 65
human studies, male, 65
insulin, 65
naloxone, 65
pancreatic polypeptide, 65
stress, 975
temperature, 975
tolerance, 975
Endo-oligopeptidase, 1017
castration
gonadal steroids
Endorphin
bladder motility, 645
central activity, 645
chicks, 823
distress vocalizations, 823
emotions, 823
enkephalins, 823
fatigue, 953
gonadotropins, 953
opioid peptides, 953
serum LH, 953
Endorphin like immunoreactivity release, 47
angiotensin II
cell culture
pituitary, rat

β-Endorphin
ACTH, 713
drinking, 691
eating, 691
HPLC, 1037
hyperthermia, 713
intestinal motility, 1037
in vitro metabolism, 1049
in vitro proteolytic processing, 1037
α-MSH, 841
opiates, 691
opiomelanotropinergic neuronal systems, 841
opioid peptides, 691
pigeons, 691
preoptic-anterior hypothalamus, 713
schizophrenia, 1049
tolerance, 713
β-Endorphin like immunoreactivity, 15
avoidance learning
behavioral training
protein malnutrition, postnatal
α-Neo-endorphin, 129
locomotor activity
multi-dimensional behavioral analyses
β-Neo-endorphin, 1011
locomotor activity
naloxone
Enkephalin
ACTH, 895
chicks, 823
corticosterone, 895
distress vocalizations, 823
emotions, 823
endorphins, 823
human adrenal medulla, 993
immunohistochemical localization, 993
immunohistochemistry, 757
naloxone, 895
pheochromocytomas, 993
radioimmunoassay, 757
stomach, 757
Enkephalin-like immunoreactivity, 931
biotin-avidin technique
highly reactive neurons
rat hypothalamus
Enkephalin receptors, 53
aged-rat brain
dihydroergotoxine
thyrotropin releasing hormone receptors
Met-enkephalin release, 849
in vitro
somatostatin
spinal cord, rat
D-Ala²-Met-Enkephalinamide, 737
blood pressure
body temperature
monkeys
opioid peptides
Enkephalinase, 649
cholecystokinin (CCK)
metalloendopeptidase
neuropeptide degradation
Enkephalinase inhibitor, 1159
ES52
noxious and non-noxious stimuli
ventrobasal thalamic neurons
Entero-insular axis, 445
dogs
pancreatic duct occlusion
vasoactive intestinal peptide (VIP)
Epidermal growth factor, 945
corneal ipithelium
hypophysectomy
mitotic index
stomach weight
Epilepsy, 429
cerebrospinal fluid
circadian variation
vasoactive intestinal peptide (VIP)
ES52, 1159
enkephalinase inhibitor
noxious and non-noxious stimuli
ventrobasal thalamic neurons
Estradiol, 313
serotonin release
suprachiasmatic nucleus
vasoactive intestinal peptide (VIP)
Ethanol
chlordiazepoxide, 809
drug interaction, 809
luteinizing hormone, s209
luteinizing hormone-releasing hormone, s209
pentobarbital, 809
pigeons, 809
thyrotropin releasing hormone, 809
Evolution, s71
corticotropin-releasing factor
hypothalamic hormones
immunoenzyme techniques
Extracerebral cranial arteries, 385
cerebral cranial arteries
dilator transmitter
vasoactive intestinal peptide (VIP)

False positives, 1007
high performance liquid chromatography
radioimmunoassay
Fatigue, 953
endorphins
gonadotropins
opioid peptides
serum LH
Fever
alpha-melanocyte-stimulating hormone, 815
antipyresis, 57
antipyretic, 815
antipyretic peptides, 57
body temperature, 91
corticotropin releasing factor, 57
muranyl dipeptide, 91
rabbits, 815
sleep-induced peptides, 91
slow-wave sleep, 91
Fiber projection, 889
aging
cholecystokinin
mammillary body
nucleus anterior ventralis thalami
Fixation, 225
genitourinary system
human studies
vasoactive intestinal peptide (VIP)
Fluorescence microscopy, 119
gonadotropin-releasing hormone internalization
Leydig cells
FMRF-NH_2, 777
insulin
islet
somatostatin
FMRFamide immunoreactivity
central nervous system, 563, 585
gastrointestinal tract, 563
horseshoe crab, 585
immunohistochemistry, 569
molluscan cardioexcitatory peptide, 569
neuromodulators, 585
neuropeptides, 569
Follicle stimulating hormone (FSH), 471
gonadotropins
hamsters
LHRH
Food and shock presentation, 783
MK-771
noxious stimuli
squirrel monkeys
stimulus-shock termination
thyrotropin-releasing hormone
Food stimulation, 35
dogs
gastrin release
Foot shock analgesia, 635
pain
thyrotropin releasing hormone
N-formylation, 653
C-blocked peptides
Frogs, 905
biosynthesis
pituitary gland
pro-opiomelanocortin
Frog skin, 133
cyclo (His-Pro)

GABA, 641
competitive binding
endogenous benzodiazepine ligands
human cerebrospinal fluid
Gallbladder, 729
ceruletide
ceruletide analogues
cholecystokinin octapeptide
guinea pigs
smooth muscle stimulation
Gastric acid secretion
calcitonin gene-related peptide, 665
central nervous system, 665
pepsin secretion, 857
somatostatin, 857
somatostatin antagonist, 857
structure-activity relationships, 857
Gastric emptying, 481
cholecystokinin
satiety
Gastric inhibitory polypeptide (GIP), 403
caloric intake
human studies
vasoactive intestinal peptide (VIP)
Gastrin release
bombesin, 29
dogs, 29, 35
food stimulation, 35
somatostatin, 29
Gastroduodenal mucosa, 411
coeliac sprue
duodenal ulcer
human studies
vasoactive intestinal peptide (VIP)

Gastrointestinal tract, 563
central nervous system
FMRFamide immunoreactivity
Gastrointestinal transit, 1055
opiate receptor
thyrotropin releasing hormone
Genetic obesity, 11
cholecystokinin
receptor binding
Genitourinary system, 225
fixation
human studies
vasoactive intestinal peptide (VIP)
GH release, s41
brain peptides
growth hormone releasing factor
hormone action
GHRF-immunoreactive structures, 1071
growth hormone releasing factor
immunocytochemistry
Gila monster venom
adenylate cyclase, 407
rat pancreatic acini, 333
rat pancreatic membranes, 407
secretin, 407
vasoactive intestinal peptide (VIP) 333, 407
Glucagon, 871
insulin
neuropeptides
regulation of endocrine pancreas
vasopressin
Glucagon-29 (pancreatic glucagon), 553
glucagon-37 (oxyntomodulin)
high performance liquid chromatography
human bowel
radioreceptorassay
Glucagon-37 (oxyntomodulin), 553
glucagon-29 (pancreatic glucagon)
high performance liquid chromatography
human bowel
radioreceptorassay
Glucose, 65
endogenous opiates
human studies, male
insulin
naloxone
pancreatic polypeptide
Glycogenolysis
cerebral cortex, 213
cortical organization, 213
cyclic AMP, 295
neuropeptides, 295
retina, 295
vasoactive intestinal peptide (VIP), 213, 295
GnRH analogs, 1001
intracellular cAMP
in vitro LH release
pituitary cell culture
GnRH agonist, s215
GnRH antagonist
gonadotropin releasing hormone (GnRH)
receptor-mediated binding
GnRH antagonist, s215
GnRH agonist
gonadotropin releasing hormone (GnRH)
receptor-mediated binding
Gonadal steroids, 1017
castration
endo-oligo peptidase
Gonadotropins
endorphins, 953
fatigue, 953
follicle stimulating hormone (FSH), 471
hamsters, 471
LHRH, 471
opioid peptides, 953
serum LH, 953
Gonadotropin-releasing hormone (GnRH)
fluorescence microscopy, 119
GnRH agonist, s215
GnRH antagonist, s215
internalization, 119
Leydig cells, 119
receptor-mediated binding, s215
Grooming, 1197
α-MSH/ACTH$_{4-10}$
neuropeptides
structure-activity
Growth hormone, 389
acromegaly
cerebrospinal fluid (CSF)
human studies
prolactin
vasoactive intestinal peptide (VIP)
Growth hormone releasing factor
brain peptides, s41
GH release, s41
GHRF-immunoreactive structures, 1071
hormone action, s41
immunocytochemistry, 1071
Guinea pig
acid secretion, 277
ceruletide, 729
ceruletide analogues, 729
cholecystokinin, 285
cholecystokinin octapeptide, 729
gallbladder, 729
histamine H$_2$ receptor, 277
peptides, 267
potentiation, 285
smooth muscle stimulation, 729
solid phase, 267
ultrastructure, 277
vagus nerve, 285
vasoactive intestinal peptide (VIP), 267, 277, 285
Guinea pig ileum, 687
dermorphin
mouse vas deferens
structure-activity relationship
synthetic peptides

Haloperidol, 883
catalepsy
Pro-Leu-Gly-NH$_2$
tolerance
Hamsters
follicle stimulating hormone (FSH), 471
gonadotropins, 471
LHRH, 471
membrane potential, 423
pancreatic ductal carcinoma, 423
transplantable pancreatic cancer, 423
Heart membranes, 341
adenylate cyclase
animal models
chronotropic responses
iontropic responses
peptide histidine isoleucine (PHI)
secretin
vasoactive intestinal peptide (VIP)
Heart membranes, human, 877
adenylate cyclase
vasoactive intestinal peptide
High performance liquid chromatography (HPLC)
β-endorphin, 1037
false positives, 1007
glucagon-29 (pancreatic glucagon), 553
glucagon-37 (oxyntomodulin), 553
human bowel, 553
intestinal motility, 1037
^{125}I-VIP, 1085
in vitro proteolytic processing, 1037
monoiodinated VIP (M^{125}I-VIP), 179
radioimmunoassay, 553, 1007
vasoactive intestinal peptide (VIP), 179, 1085
Highly reactive neurons, 931
biotin-avidin technique
enkephalin-like immunoreactivity
rat hypothalamus
Hippocampal corticosterone, 1225
autoregulation
vasopressin
Histamine H$_2$ receptor, 277
acid secretion
guinea pigs
ultrastructure
vasoactive intestinal peptide (VIP)
Histamine release, 695
mast cells
neurotensin
neurotensin analogues
structure-activity studies
Hormone
aldosterone, 299
corticosterone, 299, 895
estradiol, 313, 1017
growth hormone, 389
progesterone, 1017
prolactin, 389, 1067
luteinizing hormone, s209
Hormone action, s41
brain peptides
GH release
growth hormone releasing factor
Hormone stability, 1191
brain homogenates
melanocyte stimulating hormone
melanotropins
Horseshoe crab, 585
central nervous system
FMRFamide immunoreactivity
neuromodulators
Human adrenal medulla, 993
enkephalins
immunohistochemical localization
pheochromocytomas
Human bowel, 553
glucagon-29 (pancreatic glucagon)
glucagon-37 (oxyntomodulin)
high performance liquid chromatography
radioreceptorassay

Human brain, 701
binding sites
neuropeptide
thyrotropin-releasing hormone
Human brain peptides, 959
amino acid sequence
CCK biological activity
cholecystokinin (CCK)
Human buccal tumor, 161
in vitro translation
vasoactive intestinal peptide (VIP)
Human cerebral arteries, 329
dilatations
nerve fibers
vasoactive intestinal peptides (VIP)
Human cerebrospinal fluid, 641
competitive binding
endogenous benzodiazepine ligands
GABA
Human neuroblastoma cell, 155
peptide histidine isoleucine (PHI)
vasoactive intestinal peptide (VIP)
VIP precursors
Human PHI, 151
bovine PHI
brain-gut peptide
peptide histidine isoleucine (PHI)
VIP/PHI precursor
Human studies
acromegaly, 389
asthma, 439
blood flow, 319
bombesin-like immunoreactivity,865
bronchodilation, 439
caloric intake, 403
cerebrospinal fluid (CSF), 389, 435
circulation, 319
coeliac sprue, 411
duodenal ulcer, 411
fixation, 225
gastric inhibitory polypeptide (GIP), 403
gastroduodenal mucosa, 411
genitourinary system, 225
growth hormone, 389
hypercalcemia, 415
intestinal secretion, 271
isolation, 865
kidney, man, 441
liver disease, man, 441
memory, 819
multiple sclerosis, 435
neuroblastic tumors, 415
neuropeptides, 819
pancreatic cholera syndrome, 271
pancreatic endocrine tumors, 415
prolactin, 389
renin, 441
sequencing, 865
sex differences, human males, 819
somatostatin, 271
vasoactive intestinal peptide (VIP), 225, 271, 319, 389, 403, 411, 415, 435, 439, 441
vasopressin, 819
WDHA syndrome, 415
Human studies, male
endogenous opiates, 65
glucose, 65
insulin, 65
γ-melanotropin, 913
metyrapone, 913
naloxone, 65
pancreatic polypeptide, 65
plasma, normal human, 913
Hypercalcemia, 415
human studies
neuroblastic tumors
pancreatic endocrine tumors
vasoactive intestinal peptide (VIP)
WDHA syndrome
Hypertension, 355
adenylate cyclase
strain differences
vasoactive intestinal peptide (VIP)
Hyperthermia, 713
ACTH
β-endorphin
preoptic-anterior hypothalamus
tolerance
Hypophagia, 97
cancer anorexia
cholecystokinin
Hypophysectomy
corneal epithelium, 945
EEG voltage output, 115
epidermal growth factor, 945
mitotic index, 945
posticta1 depression, 115
stomach weight, 945
Hypothalamic hormones, s71
corticotropin-releasing factor
evolution
immunoenzyme techniques
Hypothalamic peptides, s241
peptide interaction
superfused pituitary cell system
Hypothalamo-hypophyseal system, s35
lateral retrochiasmatic area
median eminence
neuropeptides
Hypothalamo-neurohypophysial system, s121
cell culture
osmosensitivity
ultrastructure
Hypothalamus
adrenalectomy, 801
adrenergic receptors, 499
cardiovascular system, 801
catecholamine, s109
cholecystokinin, 73, 499
corticotropin releasing factor (CRF), s45
immunohistochemical localization of CRF, s45
in vitro studies, 73
in vivo studies, 499
neurotensin, s109
obesity, 73
preoptic area, 801
squirrel monkeys, s45
thyrotropin-releasing hormone, 801
Hypothermia, 7
cyclo(Leu-Gly)
D-2 dopamine receptors
stereotypy

ICI 174,864, 1015
central activity
central nervous system
delta-opioid antagonism
Immunochemistry, 247
peptide histidine isoleucine (PHI)
peptide histidine methionine (PHM)
peptide synthesis
Immunocytochemistry
brain opiocortins, 1089
central nervous system, s53, 721
corticotropin releasing factor, s53
diabetic pancreas, 451
D cells, 615
distribution, 721
GHRH-immunoreactive structures, 1071
growth hormone releasing factor, 1071
intestine, 615
intestine, neonatal rat, 231
lower brain stem, 721
α-melanocyte stimulating hormone, 721
monoclonal antibodies, 231
α MSH-specific neuronal system, 1089
pancreas, 615
radioimmunoassay, 615
somatostatin 28, 615
streptozotocin treatment, 451
VIP, 231
VIPergic innervation, 451
Immunoenzyme techniques, s71
corticotropin-releasing factor
evolution
hypothalamic hormones
Immunohistochemical localization, 993
enkephalins
human adrenal medulla
pheochromocytomas
Immunohistochemical localization of CRF, s45
corticotropin releasing factor (CRF)
hypothalamus
squirrel monkeys
Immunohistochemistry
enkephalin, 757
FMRFamide immunoreactivity, 569
mammals, 593
molluscan cardioexcitatory peptide, 569
neuropeptides, 569
peptide histidine peptide (PHI), 593
radioimmunoassay, 757
somatostatin, s91
stomach, 757
turtles, s91
vasoactive intestinal peptide (VIP), 593
Immunoreactivity
adrenal medulla, 707
aging, 623
brain, pig, 623
cholecystokinin (CCK), 623
corticotropin-releasing factor (CRF), 707
low molecular CRF, 707
tissue CRF, 707
vasoactive intestinal peptide (VIP), 623
In vitro, 849
met-enkephalin release
somatostatin
spinal cord, rat
In vitro autoradiography, 339
central nervous system
vasoactive intestinal peptide (VIP)
In vitro LH release, 1001
GnRH analogs

intracellular cAMP
pituitary cell culture
In vitro metabolism, 1049
β-endorphin
schizophrenia
In vitro proteolytic processing, 1037
β-endorphin
HPLC
intestinal motility
In vitro studies
angiotension II receptors, 1043
cholecystokinin, 73
development, s157
hypothalamus, 73
in vivo studies, s157
kidney, dog, 1043
obesity, 73
regenerated cell culture, s157
renal hypertension, 1043
transplantation, s157
vasopressin, s157
In vitro translation, 161
human buccal tumor
vasoactive intestinal peptide (VIP)
In vivo studies
adrenergic receptors, 499
cholecystokinin, 499
development, s157
in vitro studies, s157
hypothalamus, 499
regenerated cell culture, s157
transplantation, s157
vasopressin, s157
Indirect immunofluorescence, 209
cats
VIP-immunoreactive nerves
Infantile spasms, 1129
ACTH/MSH analog
amygdala
animal model
kindling
Inhibition and stimulation, 481
antagonist
bovine parathyroid hormone
uterine contraction
Insulin
central nervous system, 937
endogenous opiates, 65
FMRF-NH_2, 777
glucagon, 871
glucose, 65
human studies, male, 65
insulin receptor subtype, 937
islet, 777
naloxone, 65
nerve cell growth, 937
neuropeptides, 871
pancreatic polypeptide, 65
receptor binding kinetics, 937
regulation of endocrine pancreas, 871
somatostatin, 777
vasopressin, 871
Insulin hypoglycemia, 399
dogs
dopamine agonists
vasoactive intestinal peptide (VIP)
Insulin receptor subtype, 937
central nervous system
insulin
nerve cell growth
receptor binding kinetics
Insulin secretion, 541
corticotropin-releasing factor
pancreas
surgical stress
Internalization, 119
fluorescence microscopy
gonadotropin-releasing hormone
Leydig cells
Intestinal fluid transport, 291
angiotensin II
norepinephrine
vasoactive intestinal peptide (VIP)
Intestinal motility, 1037
β-endorphin
HPLC
in vitro proteolytic processing
Intestinal secretion, 271
human studies
pancreatic cholera syndrome
somatostatin
vasoactive intestinal peptide (VIP)
Intestine, 615
D cells
immunocytochemistry
pancreas
radioimmunoassay
somatostatin 28
Intestine, neonatal rat, 231
immunocytochemistry
monoclonal antibodies
VIP
Intracellular cAMP, 1001
GnRH analogs
in vitro LH release
pituitary cell culture
Intrathecal injections, 477
cats
shock titration
substance P
Inulin, 681
blood-CSF barrier
cerebrospinal fluid
α-MSH
Inotropic responses, 341
adenylate cyclase
animal models
chronotropic responses
heart membranes
peptide histidine isoleucine (PHI)
secretin
vasoactive intestinal peptide (VIP)
Isolated rat lungs, 21
endocrine-cell peptides
pulmonary vascular smooth muscle tone
Isolation
bombesin-like immunoreactivity, 865
human studies, 865
sequency, 865
vasoactive intestinal peptide (VIP), 183
VIP variant, 183
Isolation-induced fighting, 85
aggression
opioids
substance P
Islet, 777
FMRF-NH_2
insulin
somatostatin
Isoreceptors, 463
analgesic action
β-casomorphin
μ-receptors

Kidney, dog, 1043
angiotensin II receptors
in vitro studies
renal hypertension
Kidney, man, 441
human studies
liver disease, man
renin
vasoactive intestinal peptide (VIP)
Kidney, rats, 1217
neonatal exposure
vasopressin binding sites
Kindling, 1129
ACTH/MSH analog
amygdala
animal model
infantile spasms
Kittens, 25
active sleep
arginine vasotocin
brain maturation

Lateral retrochiasmatic area, s35
hypothalamo-hypophyseal system
median eminence
neuropeptides
Learning and memory, s249
aversion
dementia
protein binding
Lesions, dorsomedial hypothalamus, 547
body weight regulation
bombesin
cholecystokinin
eating
Lesions, spinal cord, 201
mammals
sacral spinal cord
vasoactive intestinal peptide (VIP)
Lesions, ventromedial hypothalamus, 1149
ceruletide
cholecystokinin
route of administration
satiety
Leydig cells, 119
fluorescence microscopy
gonadotropin-releasing hormone
internalization
LHRH, 471
follicle stimulating hormone (FSH)
gonadotropins
hamsters
LHRH projections, s195
mammals
reproduction
species differences
Limbic system, s139
paraventricular nucleus
vasopressin
Litorin
blood pressure, 765
bombesin, 607
drinking, 607
eating, 607
phyllolitorins, 765

ranatensin, 607
smooth muscle preparations, 765
Liver disease, man, 441
human studies
kidney, man
renin
vasoactive intestinal peptide (VIP)
Liver, pig, 367
binding sites
neuropeptides
receptor-mediated degradation
vasoactive intestinal peptide (VIP)
Localization, 1077
adrenalectomy
corticotropin releasing factor
stress
Locomotor activity
anti-depressive effects, 743
behavioral despair rats, 743
α-neo-endorphin, 129
β-neo-endorphin, 1011
multi-dimensional behavioral analyses, 129
naloxone, 1011
thyrotropin releasing hormone (TRH), 743
TRH-analogues, 743
Low molecular CRF, 707
adrenal medulla
corticotropin-releasing factor (CRF)
immunoreactivity
tissue CRF
Lower brain stem, 721
central nervous system
distribution
immunocytochemistry
α-melanocyte stimulating hormone
Luteinizing hormone, s209
ethanol
luteinizing hormone-releasing hormone
Luteinizing hormone-releasing hormone, s209
ethanol
luteinizing hormone

Mammals
immunohistochemistry, 593
lesions, spinal cord, 201
LHRH projections, s195
Merkel cells, 239
peptide histidine isoleucine (PHI), 261, 593
reproduction, s195
sacral spinal cord, 201
species differences, s195
vasoactive intestinal peptide (VIP), 201, 239, 261, 593
VIP-immunoreactivity, 239
Mammillary body, 889
aging
cholecystokinin
fiber projection
nucleus anterior ventralis thalami
Mammotrophs, 1067
adenylate cyclase
dopamine
prolactinoma
vasoactive intestinal peptide
Mast cells, 695
histamine release
neurotensin
neurotensin analogues
structure-activity studies
Median eminence, s35
hypothalamo-hypophyseal system
lateral retrochiasmatic area
neuropeptides
Mediobasal hypothalamus, 669
caudate putamen
DA uptake
α-melanocyte-stimulating hormone
MSH-release inhibiting factor-1 (MIF-1)
Melanocyte sensitivity, 1031
coat color, mice
α-MSH
Melanocyte stimulating hormone, 1191
brain homogenates
hormone stability
melanotropins
α-Melanocyte-stimulating hormone (MSH)
acetylation, 1061
antipyretic, 815
blood-CSF barrier, 681
caudate putamen, 669
central nervous system, 721
cerebrospinal fluid, 681
coat color, mice, 1031
DA uptake, 669
distribution, 721
β-endorphins, 841
fever, 815
immunocytochemistry, 721
inulin, 681
lower brain stem, 721
mediobasal hypothalamus, 669
melanocyte sensitivity, 1031
MSH-release inhibiting factor-1 (MIF-1), 669
neurointermediate lobe, 1061
opiomelanotropinergic neuronal systems, 841
rabbits, 815
Xenopus laevis, 1061
Melanotropins, 1191
brain homogenates
hormone stability
melanocyte stimulating hormone
γ-Melanotropin, 913
metyrapone
human studies, male
plasma, normal human
Melatonin, 495
circadian rhythms
delta sleep inducing peptide (DSIP)
pituitary gland
Membrane potential, 423
hamsters
pancreatic ductal carcinoma
transplantable pancreatic cancer
Memory
arginine vasotocin, 1221
avoidance, 1221
chickens, 1221
human studies, 819
neuropeptides, 819
sex differences, human males, 819
vasopressin, 819
Merkel cells, 239
mammals
vasoactive intestinal peptide (VIP)
VIP-immunoreactivity
Metabolites, 523
bombesin
dopamine
neuropeptides
Metalloendopeptidase, 649
cholecystokinin (CCK)
enkephalinase
neuropeptide degradation
Methanol extraction, 1203
cholecystokinin
c-terminal fragments
Methionine-enkephalin, 797
desensitization
dogs
down-regulation
opiate receptors
tolerance
Method
ABC (Avidin-Brain-Peroxidase Complex) method, 1089
ABC-GO (Glucose Oxidase) method, 1089
acid extraction, 623
affinity chromatography, 183
autoradiography, s221, 339, 1167
bioassay, 183
biotin-avidin-technique, 931
chromatography, 225, 1007
column system, s241
electromagnetic flowmetry, 319
electron microscopy, s71, s139, s215, 451, 993, 1179
enkephalin-like immunoreactivity, 931
fluorescence histochemistry, s109, s263
fluorescence microscopy, 119
gas chromatography, 47, 913
gas electrophoresis, 905
gel filtration, 183, 707
gel filtration chromatography, 1139
gel permeation chromatography, 865
gold immunostaining, 225
high performance liquid chromatography, 179, 189, 489, 523, 563, 585, 707, 865, 905, 1037, 1085
high pressure liquid chromatography, 641, 789, 967
high resolution NMR spectroscopy, 169
histochemistry, s221, 451
histofluorescence, s151
horseradish peroxidase, s139, s227
HPLC, 1007, 1049, 1061
immunoassay, 1007
immunochemistry, 247, 777
immunocytochemical recognition method, s227
immunocytochemistry, s19, s53, s71, s79, s109, s139, s157, s185, 195, 201, s209, 219, 225, 231, 255, s263, s269, 329, 451, 615, 627, 721, 1071, 1089
immunohistochemistry, s91, s101, s151, 213, s221, 239, 569, 593, 757, 865, 889, 995, 1097, 1173
immunoreactivity, 623, 707, 777
indirect immunofluorescence, 209, 451
ion exchange chromatography, 183, 1139

light microscopic autoradiography, 1043
light microscopic immunocytochemistry, s195
light microscopy, s215, 993
liquid chromatography, 161
methanol extraction, 623
microsequencing, 183
morphology, 451
parallel bioassay, 765
perfusion technique, 299
proteolytic processing, 1049
radioautography, 503
radioimmunoassay, s79, 133, s157, 161, 183, 201, s209, 219, 225, 239, s241, 247, 255, 261, 299, 399, 615, 757, 1007, 1061, 1085, 1097, 1173, 1213
radioimmunochemistry, 435
radioimmunocytochemistry, 329
radioreceptor assay, 53, 553, 743, 1085
repetitive excess mixed anhydride method, 167
retrograde neuroanatomical tracing method, s227
reversed-phase HPLC, 183, 1139
Scatchard analysis, 833, 917, 1043
solid-phase method, 169
solid phase synthetic method, 489
streptozotocin treatment, 451
ultrastructure, 451
Metyrapone, 913
γ-melanotropin
human studies, male
plasma, normal human
Microfilaments, 299
amphibians
calcium
prostaglandins
vasoactive intestinal peptide (VIP)
Microvilli, 789
aminopeptidase A
angiotensin I converting enzyme
carboxypeptidase
neutral endopeptidase
placenta
Mitotic index, 945
corneal epithelium
epidermal growth factor
hypophysectomy
stomach weight
Mixed anhydride method, 167
peptide synthesis
vasoactive intestinal peptide (VIP)
MK-771, 783
food and shock presentation
noxious stimuli
squirrel monkeys
stimulus-shock termination
thyrotropin-releasing hormone
Molluscan cardioexcitatory peptide, 569
FMRFamide immunoreactivity
immunohistochemistry
neuropeptides
Monkeys
autonomic nervous system, s185
blood pressure, 737
body temperature, 737
D-Ala^2-Met-enkephalinamide, 737
neurotensin, 125
opioid peptides, 737
spinal cord, s185
thermoregulation, 125
thyrotropin-releasing hormone, s185
vasomotor response, 125
Monoclonal antibodies, 231
immunocytochemistry
intestine, neonatal rat
monoclonal antibodies
VIP
Monoiodinated VIP ($M^{125}I$-VIP), 179
high performance liquid chromatography
vasoactive intestinal peptide (VIP)
Mouse vas deferens, 687
dermorphin
guinea pig ileum
structure-activity relationship
synthetic peptides
MSH-release inhibiting factor-1 (MIF-1), 669
caudate putamen
DA uptake
mediobasal hypothalamus
α-melanocyte-stimulating hormone
α-MSH/ACTH$_{4-10}$, 1197
grooming
neuropeptides
structure-activity
α-MSH-specific neuronal system, 1089
brain opiocortins
immunocytochemistry
Multi-dimensional behavioral analyses, 129
α-neo-endorphin
locomotor activity
Multiple neurotransmitter systems, 1
cholecystokinin
nucleus accumbens
Multiple sclerosis, 435
cerebrospinal fluid (CSF)
human studies
vasoactive intestinal peptide (VIP)
Muramyl dipeptide, 91
body temperature
fever
sleep-induced peptides
slow-wave sleep
μ-Receptors, 463
analgesic action
β-casomorphin
isoreceptors

Naloxone
ACTH, 895
corticosterone, 895
endogenous opiates, 65
enkephalins, 895
glucose, 65
insulin, 65
locomotor activity, 1011
β-neo-endorphin, 1011
pancreatic polypeptide, 65
Neocortical transplants, 103
aging
peptidergic neurons
Neonatal exposure, 1217
kidneys, rats
vasopressin binding sites
Nerve cell growth, 937
central nervous system
insulin
insulin receptor subtype
receptor binding kinetics
Nerve fibers, 329
dilatations
human cerebral arteries
vasoactive intestinal peptide (VIP)
Neural transplantation, s169
diabetes insipidus
neuropeptides
neurosecretion
Neuroblastic tumors, 415
human studies
hypercalcemia
pancreatic endocrine tumors
vasoactive intestinal peptide (VIP)
WDHA syndrome
Neurointermediate lobe, 1061
acetylation
α MSH
Xenopus laevis
Neurological diseases, s255
cerebrospinal fluids
neuropeptides
Neuromodulators, 585
central nervous system
FMRFamide immunoreactivity
horseshoe crab
Neuropeptide degradation, 649
cholecystokinin (CCK)
enkephalinase
metalloendopeptidase
Neuropeptide metabolism, 535
amastatin
aminopeptidase
brain peptidases
oxytocin
vasopressin
Neuropeptide metabolism, 769
active site arginine
neurotensin
neutral endopeptidase
substance P
Neuropeptide with tyrosine (NPY), s79
peptide with histidine and isoleucine (PHI)
regulatory peptides
Neuropeptide Y, 1025
drinking
eating
Neuropeptides
angel dust, 967
aging, s269
Alzheimer's disease, s269
autonomic nervous system, s101
binding sites, 367, 701
bombesin, 523
caudal neurosecretory system, s101
cerebrospinal fluids, s255
cyclic AMP, 295
diabetes insipidus, s169
dopamine, 523
eating, 81
FMRFamide immunoreactivity, 569
glucagon, 871
glycogenolysis, 295
grooming, 1197
human brain, 701
human studies, 819
hypothalamus-hypophyseal system, s35
immunohistochemistry, 569
insulin, 871

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

lateral retrochiasmatic area, s35
liver, pig, 367
median eminence, s35
memory, 819
metabolites, 523
molluscan cardioexcitatory peptide, 569
α-MSH/ACTH$_{4-10}$, 1197
neural transplantation, s169
neurological diseases, s255
neurosecretion, s169
[^{3}H]-phencyclidine, 967
receptor-mediated degradation, 367
regulation of endocrine pancreas, 871
retina, 295
rumination, 81
schizophrenia, 967
sex differences, human males, 819
sheep, 81
structure-activity, 1197
thyrotropin-releasing hormone, 701
vasoactive intestinal peptide (VIP), 295, 367
vasopressin, 819, 871
Neurophysins, 61
cloprostenol
oxytocin
sheep
Neurosecretion, s169
diabetes insipidus
neural transplantation
neuropeptides
Neurotensin
active site arginine, 769
binding assay, 917
catecholamine, s109
histamine release, 695
hypothalamus, s109
mast cells, 695
monkeys, 125
neuropeptide metabolism, 769
neurotensin analogues, 695
neutral endopeptidase, 769
purified plasma membranes, 917
rat gastric fundus smooth muscle, 917
structure-activity studies, 695
substance P, 769
thermoregulation, 125
vasomotor response, 125
Neurotensin analogues, 695
histamine
mast cells
neurotensin
structure-activity studies
Neurotensin immunoreactivity, 1179
dorsal horn
ultrastructure
Neutral endopeptidase
active site arginine, 769
aminopeptidase A, 789
angiotensin I converting enzyme, 789
carboxypeptidase, 789
microvilli, 789
neuropeptide metabolism, 769
neurotensin, 769
placenta, 789
substance P, 769
Nigrostriatal system, s263
aging
dopamine
Noradrenaline, s151
age differences
supraoptic nucleus
vasopressin-deficient neurons
Norepinephrine, 291
angiotensin II
intestinal fluid transport
vasoactive intestinal peptide (VIP)
Noxious and non-noxious stimuli, 1159
enkephalinase inhibitor
ES52
ventrobasal thalamic neurons
Noxious stimuli, 783
food and shock presentation
MK-771
squirrel monkeys
stimulus-shock termination
thyrotropin-releasing hormone
Nucleus accumbens, 1
multiple neurotransmitter systems
cholecystokinin
Nucleus anterior ventralis thalami, 889
aging
cholecystokinin
fiber projection
mammillary body

Obesity, 73
cholecystokinin
hypothalamus
in vitro studies
Open field, 529
behavioral effects
cholecystokinin
proglumide
Opiates, 691
drinking
eating
β-endorphin
opioid peptides
pigeons
Opiate receptors
desensitization, 797
dogs, 797
down regulation, 797
gastrointestinal transit, 1055
methionine-enkephalin, 797
thyrotropin releasing hormone, 1055
tolerance, 797
Opioids
aggression, 85
casomorphins, 829
chicks, 829
distress vocalizations, 829
emotions, 829
isolation-induced fighting, 85
substance P, 85
Opioid peptides
blood pressure, 737
body temperature, 737
drinking, 691
eating, 691
endorphins, 953
β-endorphin, 691
D-Ala^2-Met-enkephalinamide, 737
fatigue, 953
gonadotropins, 953
monkeys, 737
opiates, 691
pigeons, 691
serum LH, 953

Opioid peptide regulation, s9
post-translational processing
secretion
Opiomelanotropinergic neuronal system, 841
β-endorphin
α-MSH
Osmosensitivity, s121
cell culture
hypothalamo-neurohypophysial system
ultrastructure
Ovine proenkephalin, 853
purification
sequencing
Oxytocin
amastatin, 535
aminopeptidase, 535
brain peptidases, 535
cloprostenol, 61
corticotropin (ACTH), 519
neuropeptide metabolism, 535
neurophysins, 61
pituitary ACTH release, 519
sheep, 61
vasopressin, 535
vasopressin-antagonists, 519

Pain
analgesia, 747
foot shock analgesia, 635
tail-flick latencies, 747
thyrotropin releasing hormone, 635
vasopressin, 747
Pancreas
corticotropin-releasing factor, 541
D cells, 615
immunocytochemistry, 615
insulin secretion, 541
intestine, 615
radioimmunoassay, 615
somatostatin 28, 615
surgical stress, 541
Pancreatic cholera syndrome, 271
human studies
intestinal secretion
somatostatin
vasoactive intestinal peptide (VIP)
Pancreatic duct occlusion, 445
dogs
entero-insular axis
vasoactive intestinal peptide (VIP)
Pancreatic ductal carcinoma, 423
hamsters
membrane potential
transplantable pancreatic cancer
Pancreatic endocrine tumors, 415
human studies
hypercalcemia
neuroblastic tumors
vasoactive intestinal peptide (VIP)
WDHA syndrome
Pancreatic polypeptide, 65
endogenous opiates
glucose
human studies, male
insulin
naloxone
Paraventricular nucleus, s139
limbic system
vasopressin

Pentobarbital, 809
chlordiazepoxide
drug interaction
ethanol
pigeons
thyrotropin releasing hormone
Pepsin secretion, 857
gastric acid secretion
somatostatin
somatostatin antagonist
structure-activity relationships
Peptides
Ac-[cys, cys[10]], 1197
ACTH, 713, 895, 925
ACTH 1–17, 507
$ACTH_{1-24}$, 659
angiotensin I, 769
angiotensin II, 47, 291
arginine vasopressin, 25, 61, 103, 747, 1221
arginine vasotocin, 25, 1135, 1221
bombesin, 21, 29, 35, 41, 481, 523, 547, 607, 675, 765
bradykinin, 1173
calcitonin, 21, 665, 675, 861
casomorphins, 829
β-casomorphin, 463
ceruletide, 729, 1149
cholecystokinin (CCK), 11, s35, 41, 73, 81, 97, 103, 213, s255, 285, 305, 359, 499, 529, 547, 623, 649, 675, 889, 959, 1173, 1203, 1207
CCK-8, 1, 1149
cholecystokinin octapeptide, 729
corticotropin (ACTH), 519, 627, 1129
corticotropin releasing factor, 35, s45, 57, s71, s101, 103, s241, 519, 541, 627, 707, 925, 1077
oCRF41, s19
delta sleep inducing peptide (DSIP), 495, 1007
deproceptin, 463
deprolorphin, 463
dermorphin, 687
dynorphin, s227
dynorphin A (1–13), 1173
pro-dynorphin, s9
endo-oligopeptidase B, 1017
endorphin, 103
α-endorphin, 645, 823
α-neo-endorphin, 129
β-endorphin, s227, 645, 691, 713, 823, 841, 905, 1037, 1049, 1173
β-neo-endorphin, 1011
γ-endorphin, 645, 823, 1037
enkephalin, 53, s255, 769, 895
leu-enkephalin, 21, 213, 993
met-enkephalin, 213, 797, 823, 849, 993, 1173
met-enkephalin-Arg^6-Gly^7-Leu^8, 757, 993
Met-enkephalin-Arg^6-Phe^7, 757, 993
pro-enkephalin, s9
D-Ala^2-Met-enkephalinamide, 737
follicle stimulating hormone (FSH) s1, 471
GABA, 849
gastric inhibitory polypeptide (GIP), 403
gastrin, 41, 81
glucagon, 295, 675, 871
glucagon-29, 553
glucagon-37, 553
gonadotropin releasing hormone, 119, s215, 1001
growth hormone releasing factor, s41, s79, 151, s241, 1071
des-glycinamide arginine vasopressin, 1225
LH-RH, 1017
litorin, 607, 765
luteinizing hormone releasing hormone, s35, s195, s209, 389, 471
melanocyte stimulating hormone (MSH), 103, 1129, 1191
α-MSH, 669, 681, 721, 815, 841, 905, 1061, 1089, 1191
α-MSH, 669, 681, 721, 815, 841, 905, 1061, 1089, 1191
α-MSH/$ACTH_{4-10}$, 1197
γ-MSH, 905
melanotropin, 1191
melatonin, 495
MIF-1, 883
motilin, s1
MSH-release inhibiting factor-1 (MIF-1), 669
muramyl dipeptide, 91
neuropeptide with tyrosine (NPY), s79
neuropeptide Y, s79, 1025
neurophysin, s151, s269
neurotensin, s109, 125, 695, 769, 1179
^{125}I-Trp^{11}-neurotensin, 917
oxytocin, s1, 25, s35, 61, s121, s227, 481, 519, 535, 747, 871
pancreatic polypeptide, s79, 103, 675
pareptide, 883
pepsin, 1139
pepstatin, 29
peptide histidine isoleucine (PHI), 151, 155, 201, 213, 247, 255, 261, 295, 309, 341, 593
peptide histidine methionine (PHM), 247
peptide with histidine and isoleucine (PHI), s79
phyllolitorins, 765
Pro-Leu-Gly-NH_2, 883
pro-opiomelanocortin, s9
ranatensin, 607
sauvagine, 925
secretin, 189, 295, 309, 341, 359, 423
somatostatin, s1, 29, 35, s35, s91, s101, 103, 213, s241, s255, s269, 271, 305, 445, 503, 675, 777, 857
somatostatin 28, 615
substance P, 73, 85, 103, s241, s255, 305, 411, 477, 769, 833, 849, 1097, 1173
thyrotropin-releasing hormone, s1, s35, 53, s185, 389, 635, 665, 701, 743, 783, 801, 809, 899, 1055
thyroid releasing hormone, 305
thyroid stimulating hormone, 305
thyrotropin-releasing hormone, 389
trypsin, 1139
[$Δ^3$-pro^2]-tuftsin, 489
urotensin I, s101, 925
vasoactive intestinal peptide (VIP), s1, 73, 103, 143, 151, 155, 161, 167, 169, 179, 183, 195, 201, 209, 213, 219, 225, 231, 239, 255, 261, 267, 271, 277, 285, 291, 295, 305, 309, 313, 319, 325, 329, 333, 339, 341, 355, 359, 367, 371, 375, 379, 385, 389, 395, 399, 403, 407, 411, 415, 423, 429, 435, 439, 441, 445, 451, 593, 623, 837, 877, 1067, 1085
^{125}I-VIP, 1085
vasoactive intestinal polypeptide, s79
vasopressin, s35, s101, s121, s139, s151, s157, s227, s241, 519, 535, 819, 871, 1217, 1225
Peptide histidine isoleucine (PHI)
adenylate cyclase, 341
animal models, 341
bovine PHI, 151
brain-gut peptide, 151
chronotropic responses, 341
co-localisation, 255
heart membranes, 341
human neuroblastoma cell, 155
human PHI, 151
immunochemistry, 247
immunohistochemistry, 593
inotropic responses, 341
mammals, 261, 593
neuropeptide with tyrosine (NPY), s79
peptide histidine methionine (PHM), 247
peptide synthesis, 247
pigs, 255
regulatory peptides, s79
secretin, 309, 341
sympathetic nervous system, 309
tyrosine hydroxylase, 309
vasoactive intestinal peptide (VIP), 155, 255, 261, 309, 341, 593
VIP precursor, 155
VIP/PHI precursor, 151
Peptide histidine methionine (PHM), 247
immunochemistry
peptide histidine isoleucine (PHI)
peptide synthesis
Peptide interaction, s241
hypothalamic peptides
superfused pituitary cell system
Peptidergic-aminergic neuronal system, s221
Allocortex-Brainstem-Core
endocrine-automatic regulation
Peptidergic neurones, s19
Peptidergic neurons, 103
aging
neocortical transplants
Peptidergic regulation, 675
dogs
eating
vagotomy
Peptides, 267
guinea pigs
solid phase
vasoactive intestinal peptide (VIP)
Peptide synthesis
biological activities, 169
circular dichroism, 169
immunochemistry, 247
mixed anhydride method, 167
peptide histidine isoleucine (PHI), 247
peptide histidine methionine (PHM), 247
vasoactive intestinal peptide (VIP), 167, 169
[^{3}H]-Phencyclidine, 967
angel dust
neuropeptides
schizophrenia
Pheochromocytomas, 993

enkephalins
human adrenal medulla
immunohistochemical localization
Phyllolitorins, 765
blood pressure
litorin
smooth muscle preparations
Pigeons
chlordiazepoxide, 809
drinking, 691
drug interaction, 809
eating, 691
β-endorphin, 691
ethanol, 809
opiates, 691
opioid peptides, 691
pentobarbital, 809
thyrotropin releasing hormone, 809
Pigs, 255
co-localisation
peptide histidine isoleucine (PHI)
vasoactive intestinal peptide (VIP)
Pinealectomy, 1135
aggression
arginine vasotocin
Pituitary ACTH release, 519
corticotropin (ACTH)
oxytocin
vasopressin-antagonists
Pituitary gland
bio-synthesis, 905
circadian rhythms, 495
delta sleep inducing peptide (DSIP), 495
frogs, 905
melatonin, 495
pro-opiomelanocortin, 905
Pituitary hormones, s3
brain peptides
ultrashort loop feedback
Pituitary, rat, 47
angiotensin II
endorphin like immunoreactivity release
Pituitary cell culture, 1001
GnRH analogs
intracellular cAMP
in vitro LH release, 1001
Placenta, 789
aminopeptidase A
angiotensin I converting enzyme
carboxypeptidase
microvilli
neutral endopeptidase
Plasma, normal human, 913
γ-melanotropin
metyrapone
human studies, male
Platelet-activating factor, 325
adenylate cyclase
cyclic AMP phosphodiesterase
prostacyclin
vasoactive intestinal peptide (VIP)
Polymorphonuclear leukocytes, 489
bactericidal and phagocytic activity
chemotaxis
tuftsin
Postictal depression, 115
EEG voltage output
hypophysectomy
Post-translational processing, s9
opioid peptide regulation
secretion
Potentiation, 285
cholecystokinin
guinea pig
vagus nerve
vasoactive intestinal peptide (VIP)
Preoptic-anterior hypothalamus, 713
ACTH
β-endorphin
hyperthermia
tolerance
Preoptic area, 801
adrenalectomy
cardiovascular system
hypothalamus
thyrotropin-releasing hormone
Proglumide, 529
behavioral effects
cholecystokinin
open field
Prolactin, 389
acromegaly
cerebrospinal fluid
growth hormone
human studies
vasoactive intestinal peptide (VIP)
Prolactin secretion, 395
prostaglandin D_2
rat hypophysial portal blood
vasoactive intestinal peptide (VIP)
Prolactinoma, 1067
adenylate cyclase
dopamine
mammotrophs
vasoactive intestinal peptide
Pro-Leu-Gly-NH_2, 883
catalepsy
haloperidol
tolerance
Pro-opiomelanocortin, 905
bio-synthesis
frogs
pituitary gland
Prostacyclin, 325
adenylate cyclase
cyclic AMP phosphodiesterase
platelet-activating factor
vasoactive intestinal peptide (VIP)
Prostaglandins, 299
amphibians
calcium
microfilaments
vasoactive intestinal peptide (VIP)
Prostaglandin D_2, 395
prolactin secretion
rat hypophysial portal blood
vasoactive intestinal peptide (VIP)
Protein binding, s249
aversion
dementia
learning and memory
Protein malnutrition, postnatal, 15
avoidance learning
behavioral training
β-endorphin like immunoreactivity
Protein phosphorylation, 359
cholecystokinin
secretin
vasoactive intestinal peptide (VIP)
Pulmonary vascular smooth muscle tone, 21
endocrine-cell peptides
isolated rat lungs
Purification, 853
ovine proenkephalin
sequencing
Purified plasma membranes, 917
binding assay
neurotensin
rat gastric fundus smooth muscle
Rabbits, 815
antipyretic
fever
alpha-melanocyte-stimulating hormone
Racemisation, 189
secretin analogues
secretin deactivation
secretin fragments
Radioautography, 503
receptor localization
somatostatin receptors
Radioimmunoassay
circadian rhythms, 1213
CRF, 1213
D cells, 615
enkephalin, 757
false positives, 1007
immunocytochemistry, 615
immunohistochemistry, 757
intestine, 615
high performance liquid chromatography, 1007
pancreas, 615
somatostatin 28
stomach, 757
Radioreceptorassay, 553
glucagon-29 (pancreatic glucagon)
glucagon-37 (oxyntomodulin)
high performance liquid chromatography
human bowel
Ranatensin, 607
bombesin
drinking
eating
litorin
Rat brain membrane, 833
specific binding
^{3}H-substance P binding sites
Rat gastric fundus smooth muscle, 917
binding assay
neurotensin
purified plasma membranes
Rat hypophysial portal blood, 395
prolactin secretion
prostaglandin D_2
vasoactive intestinal peptide (VIP)
Rat hypothalamus, 931
biotin-avidin technique
enkephalin-like immunoreactivity
highly reactive neurons
Rat pancreatic acini, 333
Gila monster venom
vasoactive intestinal peptide (VIP)
Rat pancreatic membranes, 407
adenylate cyclase
Gila monster venom
secretin
vasoactive intestinal peptide (VIP)
Receptor binding
atrial natriuretic factor, 1167
autoradiography, 1167
brain peptides, 1167
cardiovascular system, 1167

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

cholecystokinin, 11
genetic obesity, 11
Receptor binding kinetics, 937
central nervous system
insulin
insulin receptor subtype
nerve cell growth
Receptor localization, 503
radioautography
somatostatin receptors
Receptor-mediated binding, s215
GnRH agonist
GnRH antagonist
gonadotropin releasing hormone (GnRH)
Receptor-mediated degradation, 367
binding sites
liver, pig
neuropeptides
vasoactive intestinal peptide (VIP)
Regenerated cell culture, s157
development
in vitro studies
in vivo studies
transplantation
vasopressin
Regulation of endocrine pancreas, 871
glucagon
insulin
neuropeptides
vasopressin
Regulatory peptides, s79
neuropeptide with tyrosine (NPY)
peptide with histidine and isoleucine (PHI)
REM sleep, 837
chloramphenicol
vasoactive intestinal peptide (VIP)
Renal hypertension, 1043
angiotension II receptors
in vitro studies
kidney, dog
Renin, 441
human studies
kidney, man
liver disease, man
vasoactive intestinal peptide (VIP)
Reproduction, s195
LHRH projections
mammals
species differences
Retina, 295
cyclic AMP
glycogenolysis
neuropeptides
vasoactive intestinal peptide (VIP)
Route of administration, 1149
ceruletide
cholecystokinin
lesions, ventromedial hypothalamus
satiety
Rumination, 81
eating
neuropeptides
sheep

Sacral spinal cord, 201
lesions, spinal cord
mammals
vasoactive intestinal peptide (VIP)
Satiety
ceruletide, 1149
cholecystokinin, 481, 1149
gastric emptying, 481
lesions, ventromedial hypothalamus, 1149
route of administration, 1149
Sauvagine, 925
corticotropin (ACTH)
corticotropin releasing factor (CRF)
cortisol
urotensin I
Schizophrenia
angel dust, 967
celiac disease, 1139
β-endorphin, 1049
in vitro metabolism, 1049
neuropeptides, 967
[^{3}H]-phencyclidine, 967
wheat germ proteins, 1139
Secretin
adenylate cyclase, 341, 407
animal models, 341
cholecystokinin, 359
chronotropic responses, 341
Gila monster venom, 407
heart membranes, 341
inotropic responses, 341
peptide histidine isoleucine (PHI), 309, 341
protein phosphorylation, 359
rat pancreatic membranes, 407
sympathetic nervous system, 309
tyrosine hydroxylase, 309
vasoactive intestinal peptide (VIP), 309, 341, 359, 407
Secretin analogues, 189
racemisation
secretin deactivation
secretin fragments
Secretin deactivation, 189
racemisation
secretin analogues
secretin fragments
secretin fragments, 189
racemisation
secretin analogues
secretin deactivation
Secretion, s9
opioid peptide regulation
post-translational processing
Sequencing, 865
bombesin-like immunoreactivity, 865
human studies, 865
isolation, 865
ovine proenkephalin, 853
purification, 853
Serotonin release, 313
estradiol
suprachiasmatic nucleus
vasoactive intestinal peptide (VIP)
Serum LH, 953
endorphins
fatigue
gonadotropins
opioid peptides
Sex differences, human males, 819
human studies
memory
neuropeptides
vasopressin
Sheep
cloprostenol, 61
eating, 81
neuropeptides, 81
neurophysins, 61
oxytocin, 61
rumination, 81
Shock titration, 477
cats
intrathecal injections
substance P
Sleep-inducing peptides, 91
body temperature
fever
muramyl dipeptide
slow-wave sleep
Slow-wave sleep, 91
body temperature
fever
muramyl dipeptide
sleep-induced peptides
Smooth muscle preparations, 765
blood pressure
litorin
phyllolitorins
Smooth muscle stimulation, 729
ceruletide
ceruletide analogues
cholecystokinin octapeptide
gallbladder
guinea pigs
Solid phase, 267
guinea pigs
peptides
vasoactive intestinal peptide (VIP)
Somatostatin
bombesin, 29
dogs, 29
met-enkephalin release, 849
FMRF-NH_2, 777
gastric acid secretion, 847
gastrin release, 29
human studies, 271
immunohistochemistry, s91
in vitro, 849
insulin, 777
intestinal secretion, 271
islet, 777
pancreatic cholera syndrome, 271
pepsin secretion, 857
somatostatin anatagonist, 857
spinal cord, rat, 849
structure-activity relationships, 857
turtles, s91
vasoactive intestinal peptide (VIP), 271
Somatostatin 28, 615
D cells
immunocytochemistry
intestine
pancreas
radioimmunoassay
Somatostatin antagonist, 857
gastric acid secretion
pepsin secretion
somatostatin
structure-activity relationships
Somatostatin receptors, 503
radioautography
receptor localization
Species differences, s195
LHRH projections

mammals
reproduction
Specific binding, 833
rat brain membrane
^{3}H-substance P binding sites
Spinal cord, s185
autonomic nervous system
monkeys
thyrotropin-releasing hormone
Spinal cord, rat, 849
in vitro
met-enkephalin release
somatostatin
^{3}H-Spiperone, 1207
cholecystokinin
dopamine receptor
Squirrel monkeys
corticotropin releasing factor (CRF), s45
food and shock presentation, 783
hypothalamus, s45
immunohistochemical localization of (CRF), s45
MK-771, 783
noxious stimuli, 783
stimulus-shock termination, 783
thyrotropin-releasing hormone, 783
Stereotypy, 7
cyclo (Leu-Gly)
D-2 dopamine receptors
hypothermia
Steroid hormone concentrating neurons, s227
axonal projections
Stimulus-shock termination, 783
food and shock presentation
MK-771
noxious stimuli
squirrel monkeys
thyrotropin-releasing hormone
Stomach, 757
enkephalin
immunohistochemistry
radioimmunoassay
Stomach weight, 945
corneal epithelium
epidermal growth factor
hypophysectomy
mitotic index
Strain differences, 355
adenylate cyclase
hypertension
vasoactive intestinal peptide (VIP)
Streptozotocin treatment, 451
diabetic pancreas
immunocytochemistry
VIPergic innervation
Stress
adrenalectomy, 1077
corticotropin releasing factor, 1077
dependence, 975
drinking, 975
eating, 975
endogenous opiates, 975
localization, 1077
temperature, 975
tolerance, 975
Structure-activity relationship
dermorphin, 687
gastric acid secretion, 857
grooming, 1197
guinea pig ileum, 687
mouse vas deferens, 687
α-MSH/ACTH$_{4-10}$, 1197
neuropeptides, 1197
pepsin secretion, 857
somatostatin, 857
somatostatin antagonist, 857
synthetic peptides, 687
Structure-activity studies, 695
histamine release
mast cells
neurotensin
neurotensin analogues
Substance P
active site arginine, 769
aggression, 85
cats, 477
central nervous system, 1097
intrathecal injections, 477
isolation-induced fighting, 85
neuropeptide metabolism, 769
neurotensin, 769
neutral endopeptidase, 769
opioids, 85
shock titration, 477
substance P receptor, 1097
tachykinin, 1097
Substance P receptor, 1097
central nervous system
substance P
tachykinin
^{3}H-Substance P binding sites, 833
rat brain membrane
specific binding
Superfused pituitary cell system, s241
hypothalamic peptides
peptide interaction
Supersensitivity, 375
atropine treatment
vasoactive intestinal peptide (VIP)
VIP-levels
VIP-receptors
Suprachiasmatic nucleus, 313
estradiol
serotonin release
vasoactive intestinal peptide (VIP)
Supraoptic nucleus, s151
age differences
noradrenaline
vasopressin-deficient neurons
Surgical stress, 541
corticotropin-releasing factor
insulin secretion
pancreas
Sympathetic nervous system, 309
peptide histidine isoleucine (PHI)
secretin
tyrosine hydroxylase
vasoactive intestinal peptide (VIP)
Synthetic peptides, 687
dermorphin
guinea pig ileum
mouse vas deferens
structure-activity relationship

Tachykinin, 1097
central nervous system
substance P
substance P receptor
Tail-flick latencies, 747
analgesia
pain
vasopressin
Temperature, 975
dependence
drinking
eating
endogenous opiates
stress
tolerance
Thermoregulation, 125
monkeys
neurotensin
vasomotor response
Thyroid hormone secretion, 305
thyroid stimulating hormone
vasoactive intestinal peptide (VIP)
Thyroid stimulating hormone, 305
thyroid hormone secretion
vasoactive intestinal peptide (VIP)
Thyrotropin-releasing hormone
adrenalectomy, 801
anti-depressive effects, 743
autonomic nervous system, s185
behavioral despair rats, 743
behavioral effects, 899
binding sites, 701
cardiovascular system, 801
chlordiazepoxide, 809
decortication of frontal neocortex, 899
dose-effect response curve, 899
drug interaction, 809
ethanol, 809
food and shock presentation, 783
foot shock analgesia, 635
gastrointestinal transit, 1055
human brain, 701
hypothalamus, 801
locomotor activity, 743
MK-771, 783
monkeys, s185
neuropeptide, 701
noxious stimuli, 783
opiate receptor, 1055
pain, 635
pentobarbital, 809
pigeons, 809
preoptic area, 801
spinal cord, s185
squirrel monkeys, 783
stimulus-shock termination, 783
TRH-analogues, 743
Thyrotropin releasing hormone receptors, 53
aged-rat brain
dihydroergotoxine
enkephalin receptors
Tissue CRF, 707
adrenal medulla
corticotropin-releasing factor (CRF)
immunoreactivity
low molecular CRF
Tolerance
ACTH, 713
catalepsy, 883
dependence, 975
desensitization, 797
dogs, 797
down regulation, 797
drinking, 975

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

eating, 975
endogenous opiates, 975
β-endorphin, 713
haloperidol, 883
hyperthermia, 713
methionine-enkephalin, 797
opiate receptors, 797
preoptic-anterior hypothalamus, 713
Pro-Leu-Gly-NH_2, 883
stress, 975
temperature, 975
Transplantable pancreatic cancer, 423
hamsters
membrane potential
pancreatic ductal carcinoma
Transplantation, s157
development
in vitro studies
in vivo studies
regenerated cell cultures
vasopressin
TRH-analogues, 743
anti-depressive effects
behavioral despair rats
locomotor activity
thyrotropin releasing hormone (TRH)
Tuftsin, 489
bactericidal and phagocytic activity
chemotaxis
polymorphonuclear leukocytes
Turtles, s91
immunohistochemistry
somatostatin
Tyrosine hydroxylase, 309
peptide histidine isoleucine (PHI)
secretin
sympathetic nervous sytem
vasoactive intestinal peptide (VIP)

Ultrashort loop feedback
brain peptides
pituitary hormones
Ultrastructure
acid secretion, 277
cell culture, s121
dorsal horn, 1179
guinea pigs, 277
histamine H_2 receptor, 277
hypothalamo-neurohypophysial system, s121
neurotensin immunoreactivity, 1179
osmosensitivity, s121
vasoactive intestinal peptide (VIP), 277
Urinary bladder, 219
denervation
vasoactive intestinal peptide (VIP)
Urotensin I, 925
corticotropin (ACTH)
corticotropin releasing factor
cortisol
sauvagine
Uterine contraction, 481
antagonist
bovine parathyroid hormone
inhibition and stimulation

Vagotomy, 675
dogs
eating
peptidergic regulation
Vagus nerve, 285
cholecystokinin
guinea pigs
potentiation
vasoactive intestinal peptide (VIP)
Vasoactive intestinal peptide (VIP)
acid secretion, 277
acromegaly, 389
adenylate cyclase, 325, 341, 355, 407, 877, 1067
aging, 623
amphibians, 299
angiotensin II, 291
animal models, 341
asthma, 439
atropine treatment, 375
binding sites, 367
biological activities, 169
blood flow, 319
blood mononuclear cells, 371
brain, pig, 623
bronchodilation, 439
calcium, 299
caloric intake, 403
catecholamines, 379
central nervous system, 339
cerebral cortex, 213
cerebral cranial arteries, 385
cerebrospinal fluid (CSF), 389, 429, 435
chloramphenicol, 837
cholecystokinin (CCK), 285, 359, 623
chronotropic responses, 341
circadian variation, 429
circular dichroism, 169
circulation, 319
coeliac sprue, 411
co-localisation, 255
colon, 379
cortical organization, 213
cyclic AMP, 295, 379
cyclic AMP-dependent protein kinase, 371
cyclic AMP phosphodiesterase, 325
denervation, 219
dilatations, 329
dilator transmitter, 385
dogs, 399
dopamine, 1067
dopamine agonists, 399
duodenal ulcer, 411
entero-insular axis, 445
epilepsy, 429
estradiol, 313
extracerebral cranial arteries, 385
fixation, 225
gastric inhibitory polypeptide (GIP), 403
gastrointestinal mucosa, 411
genitourinary system, 225
Gila monster venom, 333, 407
glycogenolysis, 213, 295
growth hormone, 389
guinea pigs, 267, 277, 285
heart membranes, 341
heart membranes, human, 877
high performance liquid chromatography, 179, 1085
histamine H_2 receptor, 277
huma baccal tumor, 161
human cerebral arteries, 329
human neuroblastoma cell, 155
human studies, 225, 271, 319, 389, 403, 411, 415, 435, 439, 441
hypercalcemia, 415
hypertension, 355
immunocytochemistry, 231
immunohistochemistry, 593
immunoreactivity, 623
insulin hypoglycemia, 399
intestinal fluid transport, 291
intestinal secretion, 271
intestine, neonatal rat, 231
inotropic responses, 341
in vitro autoradiography, 339
in vitro translation, 161
isolation, 183
kidney, man, 441
lesions, spinal cord, 201
liver disease, man, 441
liver, pig, 367
mammals, 201, 239, 261, 593
mammotrophs, 1067
Merkel cells, 239
microfilaments, 299
mixed anhydride method, 167
monoclonal antibodies, 231
monoiodinated VIP (M^{125} I-VIP), 179
multiple sclerosis, 435
nerve fibers, 329
neuroblastic tumors, 415
neuropeptides, 295, 367
norepinephrine, 291
pancreatic cholera syndrome, 271
pancreatic duct occlusion, 445
pancreatic endocrine tumors, 415
peptides, 267
peptide histidine isoleucine (PHI), 155, 255, 261, 309, 341, 593
peptide synthesis, 167, 169
pigs, 255
platelet-activating factor, 325
potentiation, 285
prolactin, 389
prolactin secretion, 395
prolactinoma, 1067
prostacyclin, 325
prostaglandin D_2, 395
prostaglandins, 299
protein phosphorylation, 359
rat hypophysial portal blood, 395
rat pancreatic acini, 333
rat pancreatic membranes, 407
receptor-mediated degradation, 367
REM sleep, 837
renin, 441
retina, 295
sacral spinal cord, 201
secretin, 309, 341, 359, 407
serotonin release, 313
solid phase, 267
somatostatin, 271
strain differences, 355
supersensitivity, 375
suprachiasmatic nucleus, 313
sympathetic nervous system, 309
thyroid, hormone secretion, 305
thyroid stimulating hormone, 305
tyrosine hydroxylase, 309
ultrastructure, 277
urinary bladder, 219

vagus nerve, 285
VIP-immunoreactivity, 239
VIP levels, 375
VIP precursor, 155
VIP receptors, 375
VIP variant, 183
^{125}I-VIP, 1085
WDHA syndrome, 415
^{125}I-VIP, 1085
high performance liquid chromatography
vasoactive intestinal peptide
Vasomotor response, 125
monkeys
neurotensin
thermoregulation
Vasopressin
amastatin, 535
aminopeptidase, 535
analgesia, 747
autoregulation, 1225
brain peptidases, 535
development, s157
glucagon, 871
hippocampal corticosterone, 1225
human studies, 819
in vitro studies, s157
in vivo studies, s157
insulin, 871
limbic system, s139
memory, 819
neuropeptide metabolism, 535
neuropeptides, 819, 871
oxytocin, 535
pain, 747
paraventricular nucleus, s139
regenerated cell culture, s157
regulation of endocrine pancreas, 871
sex differences, human males, 819
tail-flick latencies, 747
transplantation, s157
Vasopressin-antagonists, 519
corticotropin (ACTH)
oxytocin
pituitary ACTH release
Vasopressin binding sites, 1217
kidneys, rats
neonatal exposure, 1217
Vasopressin-deficient neurons, s151
age-differences
noradrenaline
supraoptic nucleus
Ventrobasal thalamic neurons, 1159
enkephalinase inhibitor
ES52
noxious and non-noxious stimuli
VIPergic innervation, 451
diabetic pancreas
immunocytochemistry
streptozotocin treatment
VIP-immunoreactive nerves, 209
cats
indirect immunofluorescence
VIP-immunoreactivity, 239
mammals
Merkel cells
vasoactive intestinal peptide (VIP)
VIP-levels, 375
atropine treatment
supersensitivity
vasoactive intestinal peptide (VIP)
VIP-receptors
VIP precursor, 155
human neuroblastoma cell
peptide histidine isoleucine (PHI)
vasoactive intestinal peptide (VIP)
VIP-receptors, 375
atropine treatment
supersensitivity
vasoactive intestinal peptide (VIP)
VIP-levels
VIP variant, 183
isolation
vasoactive intestinal peptide (VIP)
VIP/PHI precursor, 151
bovine PHI
brain-gut peptide
human PHI
peptide histidine isoleucine (PHI)

WDHA syndrome, 415
human studies
hypercalcemia
neuroblastic tumors
pancreatic endocrine tumors
vasoactive intestinal peptide (VIP)
Wheat germ proteins, 1139
celiac disease
schizophrenia

Xenopus laevis, 1061
acetylation
αMSH
neurointermediate lobe

AUTHOR INDEX

Abe, K., 415
Abens, J., 375
Adachi, I., 415
Adrian, T. E., 411
Aguilera, G., 1077
Ahrén, B., 305
Akil, H., s9
Akiyama, K., 1191
Amin, I. M., 429
Amoscato, A. A., 489
Anand, P., 201
Andersen, O., 435
Anderson, S., 681
Ånggård, A., 593
Anteunis, A., 277
Anthony, E. L. P., s195
Antoni, F. A., 519
Antunes-Rodrigues, J., 1017
Arilla, E., 857
Arimura, A., s41, 1071
Astesano, A., 277

Babcock, G. F., 489
Baldwin, C., 309
Banks, W. A., s249
Barrett, J. E., 783, 809
Bartfai, T., 375
Barth, A., 463
Baskin, D. G., 615
Bataille, D., 553
Beal, M. F., s255
Beck, B., 403
Beckwith, B. E., 819
Bellinger, L. L., 547
Benoist, J.-M., 1159
Berman, R. F., 1061
Bernal-Pedraza, J., 837
Bernardini, G. L., 57
Bernardis, L. L., 547
Besson, J., 339
Bevan, J. A., 209, 385
Beyerman, H. C., 167
Bhargava, H. N., 1055
Bhaskar Rao, M., 291
Bickel, M., 189
Bishop, A. E., 255
Bishop, J. F., 563, 585
Blake, M. J., 953
Blank, M. A., 201, 219
Blomquist, L.-E., 399
Bloom, F. E., 213
Bloom, S. R., s79, 201, 219, 225, 255, 261, 411
Bodnar, R. J., 635, 747
Bodner, M., 161
Boige, N., 379
Boissard, C., 179
Borrell, J., 895
Bowdy, B. D., 21
Brady, L. S., 783
Brayden, J. E., 209
Breese, G. R., 523
Bresson, J. L., s19
Brown, J. C., 231
Brown, R., 1135
Bryant, M. G., 411
Buchan, A. M. J., 231
Bueno, L., 81
Buga, G., 385
Bugnon, C., s19
Butler, P. D., 635

Calam, J., 441
Calaresu, F. R., 931
Calvo, J. R., 371
Camargo, A. C. M., 1017
Campbell, G. T., 471
Camus, J. C., 355, 407, 877
Cantin, M., 1167
Capdevila, A., 701
Cardot, J., s19
Carrasco, M. A., 15
Carter, R. J., 1031
Castrucci, A. M. L. de, 1191
Cataland, S., 291
Catt, K. J., 1077
Celis, M. E., 669
Chance, W. T., 97
Chang, D., 1173
Chang, J. K., 1173
Chang, M., 1203
Chase, T. N., 1097
Chatelain, P., 341, 355
Chayvialle, J. A., 403
Childs, G. V., 627
Chiocchio, S. R., 669
Chmielowiec, S., 627
Christofides, N. D., 255, 261
Christophe, J., 333, 341, 355, 359, 407, 877
Chronister, R. B., 1
Chronwall, B. M., 563, 569, 585, 1097
Clavequin, M. C., s19
Cody, W. L., 1191, 1197
Collins, S. M., 481
Collins, T. J., 627
Conn, P. M., s215
Contreras, P. C., 967
Copeland, M., s45
Cowan, A., 115
Cox, C. P., 325
Coy, D. H., 299, 823, 857, 877
Crandall, P. H., 429
Crawley, J. N., 1197
Culler, M. D., s41

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

Culling-Berglund, A. J., 1037
Cummings, S., s101

Dalpé, M., 1167
Damien, C., 333
Darľak, K., 687
Davis, J. L., 1221
Davis, T. P., 645, 1037, 1049
Debry, G., 403
de Caro, G., 607
Deckert, J., 641
Dees, W. L., s209
DeFrance, J. F., 1
Dehaye, J. P., 333, 359
Delarue, C., 299
de Lean, A., 1167
De Neef, P., 355, 407, 877
Desalme, A., 403
Deschodt-Lanckman, M., 649
Deveney, C. W., 959
Deviche, P., 691
Dias, R. D., 15
DiMaggio, D. A., 967
Dimaline, R., 183
Diz, D. I., 801
Dockray, G. J., 757
Domschke, S., 411
Domschke, W., 411
Dores, R. M., s9
Dorudi, S., 441
Dray, A., 645, 1015
Drucker-Colín, R., 837
Du, B.-H., 1203
Dumbrille-Ross, A., 1207
Dunning, B. E., 871
Dussaillant, M., 339

Ebner, F. F., 103
Edvinsson, L., 329
Edwards, R. M., 133
Ekman, R., 329
Elde, R. P., s101, 777
Elwin, C.-E., 399
Emani, S., 277
Eng, J., 623, 1203
Engel, J., Jr., 429
Engelbrecht, S., 769
Engelhardt, W., 445
Ensinck, J. W., 615
Erdös, E. G., 769, 789
Everist, H., 967
Eysselein, V. E., 959

Faccini, E., 849
Fahrbach, S. E., s227
Fahrenkrug, J., 367, 435, 593, 937
Falconieri Erspamer, G., 765
Farruggia, G., 765
Faudon, M., 313
Fawcett, C. P., 871
Fei, H., 1173
Fellmann, D., s19
Felt, B. T., 1225
Fernández-Cancino, F., 837
Fields, J., s151
Fields, J. Z., 7
Finkelstein, J. A., 11, 73
Fischer, J. E., 97
Fischman, A. J., 1007, 1213
Flint, A. P. F., 61
Fontaine-Perus, J., 195
Fornal, C., 91
Fournier, A., 169
Fox, J. E. T., 917
French, E. D., 967
Fridkin, M., 161
Frye, G. D., 523
Fryer, J., 925
Fujino, K., 707
Fukata, S., 247
Fukui, K., s109

Gafford, J. T., 789
Gaginella, T. S., 291
Gall, F. P., 445
Gammeltoft, S., 367, 937
Gariot, P., 403
Gash, D. M., s157, s169
Gautron, M., 1159
Gebhardt, C., 445
Gehlert, D. R., 1043
Genest, J., 1167
George, J. M., 291
Gespach, C., 277
Giannattasio, G., 1067
Gibbins, I. L., 209
Gibbs, F. P., s45, s169
Gibson, S. J., 201
Giles, T. E., 797
Gillespie, M. N., 21
Gillet, L., 355, 407
Giraud, A., 757
Gisolfi, C. V., 737
Go, V. L. W., 73
Goberna, R., 371
Goiny, M., 399
Goldman, H., 1061
Goldman, M. E., 1129
Goldstein, R., 25
Gosnell, B. A., 665, 675, 861
Gouget, A., s19
Govoni, S., 849
Gozes, I., 161
Graf, M. V., s249, 1007
Gregerson, K. A., 471
Grey, T. R., 499
Groome, J., 563, 585
Grzonka, Z., 687
Gu, J., 219
Guaza, C., 895
Guerrero, J. M., 371
Guilbaud, G., 1159
Gumbert, E., 445
Gumuľka, S. W., 687
Gurll, N. J., 737
Gutkowska, J., 1167

Hadjiyiassemis, M., s19
Hadley, M. E., 1191, 1197
Håkanson, R., 267
Halberg, F., 507
Hall, M. E., 85
Hamaoka, T., 889
Han, J. S., 1173
Handelmann, G. E., 1217
Haniuda, C., 415
Hansky, J., 41
Hartrodt, B., 463
Hartschuh, W., 239
Hashimoto, K., 707
Hashimura, E., 889
Hatton, G. I., s121
Hattori, T., 707
Hauger, R. L., 1077
Hawke, D., 183
Haycock, J. W., s263
Hazum, E., 119
Hery, F., 313
Hery, M., 313
Hirsch, J. D., 499
Hirsch, M. D., 1197
Hirschowitz, B. I., 29, 35
Hirst, B. H., 857
Hof, P., 295
Hökfelt, T., 593
Holaday, J. W., 115
Holets, V., s101
Holland, A., 65
Holmes, M. C., 519, 1077
Honde, C., 81
Hoshino, M., 155
Hruby, V. J., 1191, 1197
Hsiao, S., 529, 899
Huebner, F. R., 1139
Hughes, J. J., 665
Hulmes, J. D., 1203

Ibata, Y., s109
Ichihara, K., 623
Iguchi, K., 155,247
Imura, H., 389, 395, 913, 993
Ip, N. Y., 309
Itoh, S., 529, 899
Itoh, Z., s41
Izquierdo, I., 15

Jackson, I. M. D., s185
Jacobowitz, D. M., 103, 801
Jacobson, S., s185
Janicki, P., 687
Jenks, B. G., 905
Jennes, L., s215, s221
Jerome, C., 1149
Johansson, B. B., 435
Johnson, A. R., 769, 789
Jönsson, A.-C., 757
Joynt, R. J., s269

Kabayama, Y., 395
Kajiyama, G., 451
Kambara, A., 451
Kameya, T., 415
Kameyama, T., 129, 1011
Kanda, M., s41
Kanno, T., 285
Karch, K., 189
Kárteszi, M., 519
Kastin, A. J., s249, 823, 975, 1007
Kato, Y., 389, 395
Katsuura, G., 529, 899
Kawai, Y., 721
Kawakami, F., s109
Kayser, V., 1159
Keinan, D., 119
Kelly, J. S., 201
Kerouac, R., 695
Kervran, A., 553
Khachaturian, H., s151
Khorram, O., s3
Kimura, S., 415
King, J. C., s195
King, M. G., 1135
Kishimoto, S., 451
Kitabgi, P., 917
Kiyama, H., 889
Knigge, K. M., 1089
Knittel, J. J., 1197
Kochman, R. L., 499
Koek, L. L., s263
Koh, H., 451
König, W., 189, 407
Kordower, J. H., 747
Koulischer, D., 649
Kozlowski, G. P., s209
Krahn, D. D., 861
Kraus, J.-L., 653
Krazaścik, p., 687
Krejs, G. J., 271
Kruggel, W., 853
Krukoff, T. L., 931
Kuchling, G., s91
Kuhn, W., 641
Kulkosky, P., 1149
Kuroda, H., 53
Kwan, C.-Y., 917

Laburthe, M., 379
Lajoie, G., 653
Landis, D. M. D., s255
Larsson, O., 593
László, F. A., 519
Lauwereys, M., 649
Leboulenger, F., 299
Leccese, A. P., 659
Lechan, R. M., s185
Lederis, K., 925
Lee, J. M., 7
Lee, T. F., 125
Leroux, P., 299, 503
Levine, A. S., 665, 675, 861 1025
Levy, J. G., 231
Lewis, R. V., 853
Lieberman, K. W., 1139
Lihrmann, I., 299
Linden, J., 325
Ling, N., 721
Lipton, J. M., 57, 815
Llewellyn, K. D., 681
Loh, Y. P., 1129
Lopez, R., 945
López-Jaramillo, P., 1017
Lucas, A. M., 1031
Lumpkin, M. D., s3
Lundberg, J. M., 593
Lux, G., 411
Lyness, W. H., 659

McCann, S. M., s3
McEwen, B. S., 1225
McIntosh, C. H. S., 231
McNeill, T. H., s263, s269

Maderdrut, J. L., s71
Magistretti, P. J., 213, 295
Maier, V., 65
Makara, G. B., 519
Maley, B., 1179
Marie, J. C., 179, 339, 553
Markus, R., 91
Marshall, P. E., s255
Martin, J. B., s255
Martinez, P. A., 11
Martling, C.-R., 593
Mason-Garcia, M., 541
Massari, V. J., 833

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

Massi, M., 607
Matsumoto, K., s41, 285
Matsushita, N., 389, 395
Matthies, H., 463
Mazzanti, G., 765
Meisenberg, G., 535
Merchenthaler, I., s53, s71, 1071
Metsch, R., 645
Micanovic, R., 853
Micevych, P. E., 73
Micossi, L. G., 607
Middleton, C., s45
Millan, M. A., 1077
Miller, C., 959
Miller Ben-Avram, C., 865
Millinton, W. R., 841
Missale, C., 849
Miyoshi, A., 451
Mizuno, S., 53, 743
Mizunuma, H., s3
Mochizuki, T., 247
Mohrland, J. S., 477
Moldow, R. L., 1213
Molina, E., 29, 35
Moltz, J. H., 871
Moore, L. G., 61
Mora, F., 125
Mori, A., 53, 743
Mori, M., 133
Morice, A., 439
Morley, J. E., 665, 675, 861, 1025
Morrell, J. I., s227
Morrison, J. F. B., 201, 219
Morrison, J. H., 213
Moscowitz, M., 385
Mostofsky, D. I., 495
Mueller, G. P., 841
Mueller, R. A., 523
Munck, A., 379, 553
Murakami, K., 707
Murphy, W., s41
Mycroft, F. J., 883
Myers, R. D., 125

Nakai, Y., 913
Nakajima, T., 765
Nakao, K., 913, 993
Namiki, M., 423
Netchitailo, P., 299
Neubert, K., 463
Nicosia, S., 1067
Niimi, M., 707
Nikolics, K., 1001
Nishioka, K., 489
Nokihara, K., 247
Normansell, L., 829
Notter, M. F. D., s157
Nukina, I., 743
Nunan, L., 1015
Nyberg, B., 319

Obara, T., 423
Obata-Tsuto, H. L., s109
O'Donohue, T. L., 563, 569, 585, 833, 841, 867, 1097, 1197
O'Dorisio, T. M., 291
Oertel, W. H., s101
Ogawa, N., 53, 743
Ogino, K., 155
Ohta, H., 389, 395
Okamoto, K., 451
Okamura, H., s109
Okamura, K., 423
Oki, S., 913
Oksenberg, A., 837
Oldfield, B. J., s139
Oliva, D., 1067
Olschowka, J. A., 103, 569
Olson, G. A., 975
Olson, R. D., 975
Onstott, D., s101
Ordronneau, P., s71
Orloff, M. S., 865
Osamura, R. Y., 993
Ota, Z., 707, 743
Ottensen, B., 367, 937
Otsubo, K., 415
Owen, M. D., 737

Palkovits, M., s35, s41
Palmiter, P., s45
Pan, Y.-C. E., 1203
Pang, P. K. T., 481
Panksepp, J., 823, 829
Park, C. H., 833
Parker, C. R., Jr., 701
Pasinetti, G., 849
Paul, S., 1085
Paull, W. K., s45, s169
Pauly, J. E., 507, 945
Peart, W. S., 441
Pegues, J., 133
Pelletier, G., 503
Perfumi, M., 607
Perlmutter, L. S., s121
Perlow, M. J., 429
Perroteau, I., 299
Perry, M. L. S., 15
Pert, A., 967
Pert, C. B., 967
Petrusz, P., s71
Pfaff, D. W., s227
Pfeiffer, E. F., 65
Phelix, C. F., s45
Phelps, C. J., s151
Pico, R. M., 1221
Piekut, D. T., 1089
Pierson, W., 133
Pillai, N. P., 1055
Pipkorn, R., 267
Polak, J. M., s79, 201, 219, 225, 255, 261
Poloczek, P., 333
Pond, W. G., 623
Praissman, M., 11
Prasad, C., 133
Prieto, J. C., 371
Przedborski, S., 649
Przuntek, H., 641

Quirion, R., 833, 967, 1097, 1167

Radulovacki, M., 91
Rathe, J., 359
Ray, P., 853
Reeve, J. R., Jr., 183, 865, 959
Reinecke, M., 239
Reinsel, C. N., 21
Reynolds, D. G., 737
Richards, D. B., 57, 815
Ridley, K., 1031
Rioux, F., 695
Ritzmann, R. F., 7
Rivier, J., 925
Robberecht, P., 341, 355, 407, 877
Robineaux, R., 277
Rosselin, G., 179, 277, 339, 553
Rossi, J., III, 829
Rostene, W., 339
Rubino, R. P., 1139
Ruethrich, H.-L., 463

Sagar, S. M., s255
Said, S. I., 143, 325, 385, 1085
Salm, A. K., s121
Samson, W. K., s3
Sander, G. E., 797
Sankaran, H., 959
Sapolsky, R. M., 1225
Sasek, C. s101, 777
Sassard, J., 355
Sato, H., 155
Saunders, J. K., 169
Saunders, W. S., 713
Sawyer, T. K., 1197
Sayson, S. C., 1217
Schaaper, W. M. M., 167
Schally, A. V., s71, s241, 541
Scharoun, S. L., s157
Schepers, G., 691
Scheving, L. A., 945
Scheving, L. E., 507, 945
Schmechel, D. E., s101
Schneider, V., 819
Schoemaker, H., 1037, 1049
Schorderet, M., 295
Schusdziarra, V., 65
Schwanzel-Fukuda, M., s227
Schwille, P. O., 445
Scott, D. E., s169
Seeman, P., 1207
Sever, P. S., 439
Seybold, V. S., s101, 1179
Shani, Y., 161
Shapiro, K. N., 429
Sharpless, N. S., 429
Shaw, B., 857
Sheldrick, E. L., 61
Sherman, D., s169
Shew, R. L., 481
Shibasaki, T., 721
Shiloach, J., 967
Shimada, A., 415
Shimatsu, A., 389, 395
Shimizu, S., 451
Shiosaka, S., 721, 889
Shively, J. E., s41, 183, 865, 959
Shoemaker, W. J., 213
Shults, C. W., 833, 1097
Shuster, S., 1031
Sickle, J., 809
Sievert, C. E., 675
Sikes, R. W., 1
Sikora, L. K. J., 231
Silvermann, A.-J., s139
Silvis, S. E., 665, 675
Simansky, K. J., 1149
Simmons, W. H., 535
Singh, J., 441
Siviy, S., 829
Skidgel, R. A., 769, 789
Sladek, J. R., Jr., s151
Smith, G. C., 41
Smith, G. P., 1149
Snapper, S. B., s185
Snook, G., 681
Shwartz, H., 161
Sobel, D. O., 47
Sonnenfeld, T., 319
Sorenson, R. L., s101, 777
Spada, A., 1067
Speth, R. C., 1043
Spieler, H.-T., 463
Spona, J., 1001
Stark, H., 463
Staun-Olsen, P., 367, 937
Steggles, A. W., 11
Stein, E. A., 953
Stewart, J. M., 85
St-Pierre, S., 169, 695
Straus, E., 623
Stumpf, W. E., 215, 221
Suen, M. Z., 1173
Suzuki, M., 415
Suzuki, T., 155
Suzuki, Y., 423
Svoboda, M., 333

Tabaddor, K., 429
Takami, K., 889
Tamaru, T., 451
Tanaka, I., 913
Tanaka, M., 247
Tang, J., 1173
Tateishi, K., 889
Tatemoto, K., 151, 593
Teetz, V., 189
Terenghi, G., 219
Terubayashi, H., s109
Thal, L. J., 429
Thody, A. J., 1031
Thomas, C. R., 1071
Thomas, R. A., 133
Thornhill, J. A., 713
Thulin, L., 319
Till, R. E., 819
Tizabi, Y., 833
Tohyama, M., 721, 889
Torre, E., 669
Torres-Aleman, I., 541
Tortella, F. C., 115
Tourtellotte, W. W., 959
Trabucchi, M., 849
Triepel, J., s91
Tsai, T. H., 507, 945
Tsuto, T., s109
Tweedle, C. D., s121
Tyden, G., 319

Ueda, N., 423
Uhmann, R., 189
Ukai, M., 129, 1011
Ulmer, M., 403
Unwin, R. J., 439, 441
Utsumi, M., 423
Uvnäs-Moberg, K., 399
Uzumaki, U., 849

Vallar, L., 1067
Vandermeers, A., 359
Vandermeers-Piret, M. C., 359
van Lammeren, F. M., 97
van Overbeeke, A. P., 905
Vaudry, H., 299, 905
Vigh, S., s71, s241

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.

Vilberg, T. R., 823
Villaume, C., 403
Vincent, J. P., 917
Vincent, M., 355
Vomachka, A. J., 953

Waelbroeck, M., 341, 407, 877
Wall, J. S., 1139
Walsh, J. H., 865, 959
Waltz, J. M., 429
Wamsley, J. K., 1043
Watanabe, K., 993
Watkins, W. B., 61
Watson, W. H., III, 563, 585
Watson, S. J., s9
Webber, R. J., 1173
Wei, E. T., 883
Weihe, E., 239
Weindl, A., s91
Weingarten, H. P., 481
Westlind, A., 375
Westlund, K. N., 627
Widerlöv, E., 523
Wikkelsø, C., 435
Wilber, J. F., 133
Wilkes, B. C., 1191
Willis, G. L., 41
Wilson, J. F., 681
Wilson, R., 1197
Winand, J., 333, 359
Witkin, J. M., 809
Wolf, D. L., 477
Wood, K., 1085
Wynn, P. C., 627, 1077

Xie, C. W., 1173

Yagura, A., 721
Yaksh, T. L., 73
Yalow, R. S., 623, 1203
Yamaguchi, K., 415
Yamamoto, M., 451, 743
Yamamoto, Y., 247
Yamamura, H. I., 1191
Yamazoe, M., 721
Yanaihara, C., 155, 247
Yanaihara, N., 155, 239, 247, 395, 415, 451, 765
Yehuda, S., 495
Yen, J. T., 623
Yiangou, Y., 255
Yoshikawa, K., 899
Yoshimasa, T., 913, 993

Zadina, J. E., s249
Zetler, G., 729
Zigmond, R. E., 309
Zolovick, A. J., 829

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction V . . .* Suppl., Vol. 5, 1984.